Injection therapies for Achilles tendinopathy by Kearney, Rebecca S. et al.
  
 
 
 
warwick.ac.uk/lib-publications 
 
 
 
 
 
Original citation: 
Kearney, Rebecca S., Parsons, Nicholas R., Metcalfe, David and Costa, Matthew L. (2015) 
Injection therapies for Achilles tendinopathy. Cochrane Database of Systematic Reviews . 
doi:10.1002/14651858.CD010960.pub2 
 
Permanent WRAP URL: 
http://wrap.warwick.ac.uk/100504            
 
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work by researchers of the 
University of Warwick available open access under the following conditions.  Copyright © 
and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners.  To the extent reasonable and practicable the 
material made available in WRAP has been checked for eligibility before being made 
available. 
 
Copies of full items can be used for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge.  Provided that the authors, title and full 
bibliographic details are credited, a hyperlink and/or URL is given for the original metadata 
page and the content is not changed in any way. 
 
Publisher’s statement: 
This review is published as a Cochrane Review in the Cochrane Database of Systematic 
Reviews 2015, Cochrane Reviews are regularly updated as new evidence emerges and in 
response to comments and criticisms, and the Cochrane Database of Systematic Reviews 
should be consulted for the most recent version of the Review. 
 
http://dx.doi.org/10.1002/14651858.CD010960.pub2 
 
A note on versions: 
The version presented in WRAP is the published version or, version of record, and may be 
cited as it appears here. 
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk 
 
Cochrane Database of Systematic Reviews
Injection therapies for Achilles tendinopathy (Review)
Kearney RS, Parsons N, Metcalfe D, Costa ML
Kearney RS, Parsons N, Metcalfe D, Costa ML.
Injection therapies for Achilles tendinopathy.
Cochrane Database of Systematic Reviews 2015, Issue 5. Art. No.: CD010960.
DOI: 10.1002/14651858.CD010960.pub2.
www.cochranelibrary.com
Injection therapies for Achilles tendinopathy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
7BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
19DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
21AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
22ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
22REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
24CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
53DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Injection therapies versus placebo injection or no injection control, Outcome 1 VISA-A (score
0 to 100; 100 = no problems): at 6 weeks. . . . . . . . . . . . . . . . . . . . . . . . . 55
Analysis 1.2. Comparison 1 Injection therapies versus placebo injection or no injection control, Outcome 2 VISA-A (score
0 to 100; 100 = no problems): at 3 months. . . . . . . . . . . . . . . . . . . . . . . . 56
Analysis 1.3. Comparison 1 Injection therapies versus placebo injection or no injection control, Outcome 3 VISA-A (score
0 to 100; 100 = no problems): after 3 months. . . . . . . . . . . . . . . . . . . . . . . 57
Analysis 1.4. Comparison 1 Injection therapies versus placebo injection or no injection control, Outcome 4 Patients
achieving increased VISA-A scores (20 points or more from baseline). . . . . . . . . . . . . . . 58
Analysis 1.5. Comparison 1 Injection therapies versus placebo injection or no injection control, Outcome 5 Adverse
events. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
Analysis 1.6. Comparison 1 Injection therapies versus placebo injection or no injection control, Outcome 6 Pain (VAS;
score 0 to 100; 0 = no pain) up to 3 months. . . . . . . . . . . . . . . . . . . . . . . . 60
Analysis 1.7. Comparison 1 Injection therapies versus placebo injection or no injection control, Outcome 7 Return to
sports. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
Analysis 1.8. Comparison 1 Injection therapies versus placebo injection or no injection control, Outcome 8 Patient
satisfaction with treatment (an event represents satisfaction with treatment). . . . . . . . . . . . . 62
Analysis 2.1. Comparison 2 Injection therapies versus active treatment, Outcome 1 VISA-A (score 0 to 100; 100 = no
problems). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
Analysis 2.2. Comparison 2 Injection therapies versus active treatment, Outcome 2 Patients achieving increased VISA-A
scores (20 points or more from baseline). . . . . . . . . . . . . . . . . . . . . . . . . 64
Analysis 2.3. Comparison 2 Injection therapies versus active treatment, Outcome 3 Adverse events. . . . . . . 65
Analysis 2.4. Comparison 2 Injection therapies versus active treatment, Outcome 4 Quality of life: EQ-5D (scores up to 1:
full health). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
Analysis 2.5. Comparison 2 Injection therapies versus active treatment, Outcome 5 Patient satisfaction with treatment
(satisfied patients). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
Analysis 3.1. Comparison 3 High-dose versus low-dose injection therapy, Outcome 1 Adverse events. . . . . . . 67
Analysis 3.2. Comparison 3 High-dose versus low-dose injection therapy, Outcome 2 Pain during activity (VAS; score 0 to
100; 0 = no pain) after maximum of 3 treatments. . . . . . . . . . . . . . . . . . . . . . 67
Analysis 3.3. Comparison 3 High-dose versus low-dose injection therapy, Outcome 3 Patient satisfaction (satisfied
patients). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
68APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
74CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
74DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
74SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
75DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
iInjection therapies for Achilles tendinopathy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
75NOTES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
75INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iiInjection therapies for Achilles tendinopathy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Injection therapies for Achilles tendinopathy
Rebecca S Kearney1, Nick Parsons2, David Metcalfe3, Matthew L Costa4
1Warwick Medical School, University of Warwick, Coventry, UK. 2Warwick Orthopaedics, Warwick Medical School, University of
Warwick, Coventry, UK. 3Division of Trauma, Burns, and Surgical Critical Care, Brigham and Women’s Hospital, Boston, USA.
4NuffieldDepartment ofOrthopaedics, Rheumatology andMusculoskeletal Sciences (NDORMS),University ofOxford, JohnRadcliffe
Hospital, Oxford, UK
Contact address: Rebecca S Kearney, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK.
R.S.Kearney@warwick.ac.uk.
Editorial group: Cochrane Bone, Joint and Muscle Trauma Group.
Publication status and date: New, published in Issue 5, 2015.
Review content assessed as up-to-date: 20 April 2015.
Citation: Kearney RS, Parsons N,Metcalfe D, Costa ML. Injection therapies for Achilles tendinopathy. Cochrane Database of Systematic
Reviews 2015, Issue 5. Art. No.: CD010960. DOI: 10.1002/14651858.CD010960.pub2.
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Achilles tendinopathy is a common condition, often with significant functional consequences. As a wide range of injection treatments
are available, a review of randomised trials evaluating injection therapies to help inform treatment decisions is warranted.
Objectives
To assess the effects (benefits and harms) of injection therapies for people with Achilles tendinopathy.
Search methods
We searched the following databases up to 20 April 2015: the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register,
the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, AMED, CINAHL and SPORTDiscus. We
also searched trial registers (29 May 2014) and reference lists of articles to identify additional studies.
Selection criteria
We included randomised and quasi-randomised controlled trials evaluating injection therapies in adults with an investigator-reported
diagnosis of Achilles tendinopathy. We accepted comparison arms of placebo (sham) or no injection control, or other active treatment
(such as physiotherapy, pharmaceuticals or surgery).Our primary outcomeswere function, usingmeasures such as theVISA-A (Victorian
Institute of Sport Assessment-Achilles questionnaire), and adverse events.
Data collection and analysis
Two review authors independently extracted data from the included studies. We assessed treatment effects using mean differences
(MDs) and 95% confidence intervals (CIs) for continuous variables and risk ratios (RRs) and 95% CIs for dichotomous variables. For
follow-up data, we defined short-term as up to six weeks, medium-term as up to three months and longer-term as data beyond three
months. We performed meta-analysis where appropriate.
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Main results
We included 18 studies (732 participants). Seven trials exclusively studied athletic populations. The mean ages of the participants in the
individual trials ranged from 20 years to 50 years. Fifteen trials compared an injection therapy with a placebo injection or no injection
control, four trials compared an injection therapy with active treatment, and one compared two different concentrations of the same
injection. Thus no trials compared different injection therapies. Two studies had three trial arms and we included them twice in two
different categories. Within these categories, we further subdivided injection therapies by mode of action (injury-causing versus direct
repair agents).
The risk of bias was unclear (due to poor reporting) or high in six trials published between 1987 and 1994. Improved methodology
and reporting for the subsequent trials published between 2004 and 2013 meant that these were at less risk of bias.
Given the very low quality evidence available from each of four small trials comparing different combinations of injection therapy versus
active treatment and the single trial comparing two doses of one injection therapy, only the results of the first comparison (injection
therapy versus control) are presented.
There is low quality evidence of a lack of significant or clinically important differences in VISA-A scores (0 to 100: best function)
between injection therapy and control groups at six weeks (MD 0.79, 95% CI -4.56 to 6.14; 200 participants, five trials), three months
(MD -0.94, 95% CI -6.34 to 4.46; 189 participants, five trials) or between six and 12 months (MD 0.14, 95% CI -6.54 to 6.82; 132
participants, three trials). Very low quality evidence from 13 trials showed little difference between the two groups in adverse events
(14/243 versus 12/206; RR 0.97, 95% CI 0.50 to 1.89), most of which were minor and short-lasting. The only major adverse event in
the injection therapy group was an Achilles tendon rupture, which happened in a trial testing corticosteroid injections. There was very
low quality evidence in favour of the injection therapy group in short-term (under three months) pain (219 participants, seven trials)
and in the return to sports (335 participants, seven trials). There was very low quality evidence indicating little difference between
groups in patient satisfaction with treatment (152 participants, four trials). There was insufficient evidence to conclude on subgroup
differences based on mode of action given that only two trials tested injury-causing agents and the clear heterogeneity of the other 13
trials, which tested seven different therapies that act directly on the repair pathway.
Authors’ conclusions
There is insufficient evidence from randomised controlled trials to draw conclusions on the use, or to support the routine use, of
injection therapies for treating Achilles tendinopathy. This review has highlighted a need for definitive research in the area of injection
therapies for Achilles tendinopathy, including in older non-athletic populations. This review has shown that there is a consensus in the
literature that placebo-controlled trials are considered the most appropriate trial design.
P L A I N L A N G U A G E S U M M A R Y
Injection treatment for painful Achilles tendons in adults
Background and aim of the review
The Achilles tendon connects the calf muscles to the heel bone. Painful and stiff Achilles tendons are common overuse injuries in
people undertaking sports, such as running, but also occur for other reasons in inactive people. The underlying cause is an imbalance
between the damage and repair processes in the tendon. Painful Achilles tendons are often disabling and can take a long time to get
better. Many treatments exist for this condition and this review set out to find out whether treatment with an injection, with a variety
of agents, decreases pain and allows people to return to their previous activities.
Results of the search
We searchedmedical databases up to 20 April 2015 for studies that compared injection therapy with a placebo injection or no injection,
or with an active treatment such as exercises, or different doses or types of injection therapy. We found 18 studies, which included 732
participants. Seven studies included athletes only. Study participants in the individual studies were mainly young to middle aged adults.
Key results
In 15 studies, patients had been assigned randomly to receive an injection therapy (such as a steroid), a placebo injection, or no injection
at all. There were several different types of injection agents used and so we separated them into those agents that acted by causing
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damage to the tendon and those that acted to repair the tendon directly. However, there were not enough data to distinguish between
these two types of injection therapies and so we only report the overall results for all injection therapies.
The review of the evidence from these studies found no clinically important difference between the injection therapy or placebo or no
injection groups in patient function scores at six weeks, three months or subsequently. Similar numbers of minor adverse events, such
as pain during the injection, occurred in both groups. The only serious adverse event in the injection therapy group was an Achilles
tendon rupture, which happened in a study testing steroid injections. There was some evidence that injection therapy may help get
patients back to sporting activities and decrease pain in the short term, but there was no evidence indicating a difference between groups
in patient satisfaction with treatment.
The evidence for the other comparisons, such as injection therapy versus exercises, made by single studies was too limited to report
here.
Quality of the evidence
Most of the studies had some aspects that could undermine the reliability of their results. We decided the evidence was of low or very
low quality for all outcomes. Thus, the findings remain uncertain and further research may provide evidence that could change our
conclusions.
Conclusions
The currently available evidence is insufficient to support the routine use of injection therapies for painful Achilles tendons in adults.
Future studies are needed to provide definitive evidence for this potentially important treatment.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Injection therapies versus placebo injection or no injection control for people with Achilles tendinopathy
Population: individuals with an invest igator-reported diagnosis of Achilles tendinopathy (or related term inology, e.g. tendinit is). We excluded trials focusing on the treatment
of individuals with systemic condit ions (e.g. rheumatoid arthrit is and diabetes)1
Setting: primary or secondary care
Intervention: inject ion therapies for Achilles tendinopathy
Comparison: no inject ion control or placebo (sham) treatment
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
No injection control
placebo injection
Injection therapy
VISA-A (score 0 to 100;
100 = no problems)
At 6 weeks
The mean VISA-A
scores across control
groups ranged f rom 57
to 71
The mean VISA-A in
the intervent ion groups
was 0.8 points higher
(4.6 points lower to 6.1
points higher)
M D 0.79
(-4.56 to 6.14)
200 (5 RCTs) ⊕⊕©©
low2
These results do not in-
clude the putat ive MCID
of 12 points3
VISA-A (score 0 to 100;
100 = no problems)
At 3 months
The mean VISA-A
scores across control
groups ranged f rom 61
to 84
The mean VISA-A in
the intervent ion groups
was 0.9 points lower
(6.3 points lower to 4.5
points higher)
M D -0.94
(-6.34 to 4.46)
189 (5 RCTs) ⊕⊕©©
low2
These results do not in-
clude the putat ive MCID
of 12 points3
VISA-A (score 0 to 100;
100 = no problems)
Af ter 3 months (6 to 12
months)
The mean VISA-A
scores across control
groups ranged f rom 73
to 82
The mean VISA-A in
the intervent ion groups
was 0.1 points lower
(6.5 points lower to 6.8
points higher)
M D 0.14
(-6.54 to 6.82)
132 (3 RCTs) ⊕⊕©©
low4
These results do not in-
clude the putat ive MCID
of 12 points3
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Adverse events
At f inal follow-up
46 per 10005 45 per 1000
(23 to 87)
RR 0.97
(0.50 to 1.89)
449 (13 RCTs) ⊕©©©
very low6
The only major adverse
event of inject ion ther-
apy was a tendon rup-
ture in a trial test ing lo-
cal steroid inject ion
Pain (VAS; score 0 to
100; 0 = no pain)
Follow-up to 3 months
The mean pain scores
across control groups
ranged f rom 10 to 78
The mean pain score in
the intervent ion groups
was 22.9 points lower
(37.5 to 8.4 points
lower)
M D -22.94
(-37.53 to -8.36)
219 (7 RCTs) ⊕©©©
very low7
The mean values were
extracted f rom graphs
and the SDs imputed for
5 of the 67 RCTs (73%
of the weight)
5 RCTs (172 part ici-
pants (78.5%)) were in
athletes
Return to sports
At f inal follow-up
563 per 10008 783 per 1000
(563 to 1000)
RR 1.39
(1.00 to 1.94)
335 (7 RCTs) ⊕©©©
very low9
4 RCTs (266 part ici-
pants (79.4%)) were in
athletes
Patient satis-
faction (number of par-
ticipants satisfied with
their treatment)
At f inal follow-up
584 per 10008 613 per 1000
(444 to 859)
RR 1.05
(0.76 to 1.47)
152 (4 RCTs) ⊕©©©
very low10
-
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; M CID: minimum clinically important dif f erence; M D: mean dif ference; RCT: randomised controlled trial; RR: risk rat io; SD: standard deviat ion; VISA-A
= Victorian Inst itute of Sport Assessment-Achilles quest ionnaire
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Of the 15 studies (600 part icipants) making this comparison, 7 studies included athletes only. Study part icipants in the
individual trials were mainly young to middle aged adults (mean ages of studies ranged f rom 20 to 50 years).5
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2We downgraded the evidence one level for lim itat ions in the design and implementat ion (4 of the 5 trials were at risk of bias,
either performance bias or other bias) and one level for imprecision: we imputed the SDs for 3 of the 5 trials (> 36% of the
weight).
3The MCID of 12 points was proposed in De Vos 2010.
4We downgraded the evidence one level for lim itat ions in the design and implementat ion (2 of the 3 trials were at risk of bias,
either performance bias or other bias) and one level for imprecision: there were fewer part icipants at this t ime point and we
imputed the SDs for 1 of the 3 trials (18% of the weight).
5This is the mean event rate. Ten of 13 RCTs had no events in the control group and thus the median event rate was 0.
6We downgraded the evidence two levels for serious imprecision (few or zero events in individual trials) and one level for
indirectness (the majority of adverse events were minor and their impact was not stated).
7We downgraded the evidence one level for lim itat ions in the design and implementat ion (e.g. 4 of the 7 RCTs failed to
document or include random sequence generat ion or allocat ion concealment), one level for inconsistency (the studies were
signif icant ly heterogeneous; I2 = 65%), and one level for imprecision ref lect ing the wide conf idence interval.
8The basis for the assumed risk was the median control group risk across studies.
9We downgraded the evidence one level for lim itat ions in the design and implementat ion (5 of the 7 RCTs failed to document or
include random sequence generat ion, allocat ion concealment or blinding of outcome assessment), one level for inconsistency
(the studies were signif icant ly heterogeneous; I2 = 84%), and one level for indirectness relat ing to the t im ing of the pain
outcome, which was too early in several trials to represent f inal outcome.
10We downgraded the evidence one level for lim itat ions in the design and implementat ion (3 of the 4 RCTs were at high risk
of bias for one domain) and one level for imprecision, ref lect ing the wide conf idence interval.
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B A C K G R O U N D
Description of the condition
The Achilles tendon connects the calf muscles (gastrocnemius,
soleus and plantaris) to the heel bone (calcaneus). It transmits
muscular forces that effect plantarflexion of the ankle against re-
sistance (such as when standing on tiptoes). It has a fundamental
role in walking and locomotion in general.
The tendon is composed of a parallel alignment of collagen, which
consists of long strandedmolecules called ’tropocollagen’ organised
into small overlapping bundles. The molecular strands are cross
linked to each other, like a rung of ladders, that have a crimped
configuration at rest, but straighten when under tension (Evans
2000)
When the Achilles tendon is subject to greatly increased forces
(e.g. sudden increase in intensity of an exercise activity) or repeti-
tive submaximal forces over a prolonged duration, such as in long-
distance running, these cross-links begin to fail across the length
of the tendon. This process is followed by a period of remodelling
and repair of the damaged tendon. When there is an imbalance
between damage and repair, the tendon may begin to exhibit char-
acteristics associated with Achilles tendinopathy, which is some-
times known as ’Achilles tendinitis’. The term tendinitis is less
frequently used because it is a term that implies there is in under-
lying inflammation. Although the role of inflammation has long
been debated, it is accepted that tendinopathy is a degenerative
condition that subsequently predisposes to other injuries such as
Achilles tendon rupture (Narici 2008; Riley 2008).
Achilles tendinopathy occurs at either the heel bone (insertion) or
mid-portion (3 cm to 6 cm from the heel bone). The insertion
of the Achilles tendon is thought to be predisposed to develop-
ing tendinopathy because of the excessive shear and compressive
forces that occur at this site. Tendinopathy at the mid-portion
(also called the ’mid-substance’), where the calf muscles attach, has
been attributed to decreased vascularity as the tendon fibres spiral
laterally through 90 degrees at this point (Riley 2008).
Factors associated with Achilles tendinopathy include biomechan-
ical faults (hyperpronation of the foot), systemic diseases (such as
diabetes), smoking, age, activity level (exercise intensity and alter-
ation in intensity) and obesity. However, the aetiology is probably
multifactorial rather than the result of any one of these consider-
ations (Kraemer 2012; Van Sterkenburg 2011).
Common features of Achilles tendinopathy include pain and stiff-
ness, particularly over the lower portion of the calf. There may
also be thickening of the tendon and swelling. Although classi-
cally worse in the morning, the pain may be constant or intermit-
tent and aggravated either during or after weight-bearing exercise
(Maffulli 2010). Pain on weight bearing in previously active peo-
ple may cause considerable disruption to activities of daily living,
work and sports.
One study in the Netherlands estimated the annual incidence of
symptoms attributable to Achilles tendinopathy in the general
population at 2.01 per 1000 people (De Jonge 2011). The an-
nual incidence for mid-portion Achilles tendinopathy was 1.85
per 1000 people. The annual median age at presentation for mid-
portion tendinopathy was 43.4 years; in 34.6% of cases, a specific
relationship to sporting activities was noted. However, this study
used Dutch general practitioner (GP) practice records and is likely
to have underestimated the true incidence as people may have pre-
sented to other healthcare practitioners (e.g. physiotherapists) or
not presented at all.
Description of the intervention
There is a large array of non-surgical (conservative) interventions
available for the management of Achilles tendinopathy (Andres
2008; Kearney 2010; Sussmilch-Leitch 2012). Examples include
eccentric exercises, cryotherapy, extracorporeal shockwave therapy,
low-level laser therapy, ultrasound, orthotics, splints, topical ni-
troglycerin, injections and non-steroidal anti-inflammatory drugs
(NSAIDS). Our review focuses on injection therapies, of which
there are a growing number in use (Coombes 2010).
Injection therapies include a range of options such as
corticosteroids, high-volume saline, prolotherapy, autologous
blood, platelet-rich plasma, aprotinin, botulinum toxin, sodium
hyaluronate, polysulphated glycosaminoglycan and polidocanol
(Coombes 2010).
Injection therapies can be guided by real-time ultrasound imaging
or unguided; they can be administered in isolation or in combina-
tion with any of the above interventions; they can be administered
in a single dose or consist of a course; and they can be injected
locally into the tendon or targeted at specific sites (such as areas of
vascular ingrowth). There is no consensus onmany of these factors
and the exact intervention is at the discretion of the responsible
clinician (Maffulli 2010).
How the intervention might work
All injection therapies are used to deliver a drug directly to the
damaged tendon. In general, these substances are thought to act ei-
ther pharmacologically (e.g. corticosteroids) or mechanically (e.g.
high-volume saline to disrupt neovascular growth).
The injection therapies reported in previous systematic reviews
(Coombes 2010; DTB 2012) are listed below together with a brief
descriptionof their proposedmechanismof action. In broad terms,
they have been classified into two groups. Firstly those stimulating
repair activity through causing injury and/or destruction of new
vascular ingrowth, which is thought to be a source of pain as this
new vascular ingrowth is often accompanied by the proliferation
of nerve endings. Secondly those targeting the promotion of repair
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activity through the introduction of substances to act directly on
the repair pathway.
Agents causing injury or disrupting vascular ingrowth
to promote repair activity
1. High-volume saline: a saline solution is injected along the
surface of the Achilles tendon, with or without local anaesthetic.
The injection produces a mechanical effect on the new vascular
ingrowth associated with tendinopathy, resulting in the new
blood vessels stretching and breaking.
2. Polidocanol: targeted disruption of new vasculature by
administration of a scelerosant to precipitate blood vessel fibrosis.
3. Prolotherapy: hypertonic glucose injected locally to initiate
repair activity by causing local tissue trauma.
Agents acting directly on the repair pathway
1. Autologous blood: injected locally to promote repair
activity through the administration of growth factors (present in
a person’s own blood) directly to the site of injury.
2. Platelet-rich plasma: injected locally to promote repair
activity through the administration of concentrated growth
factors (present in a person’s own blood that has been spun at a
high speed to separate out the platelet-rich plasma layer) directly
to the injury site.
3. Aprotinin: injected locally to inhibit collagenase, which
would otherwise break down collagen and has been found to be
increased in tendinopathy.
4. Polysulphated glycosaminoglycan: injected locally to
prevent destruction and facilitate repair through inhibiting
metalloproteinase enzyme activity.
5. Botulinum toxin: injected locally to decrease tensile stress
through the tendon and inhibit substance P, which is increased in
tendinopathy.
6. Sodium hyaluronate: injected locally to absorb mechanical
stress and provide a protective buffer for tissues.
7. Corticosteroid: injected locally to down regulate (acting to
decrease) inflammation in the affected tendon.
Injection therapies have a common suite of potential adverse ef-
fects, including local infection, bleeding, swelling and tendon rup-
ture. Adverse effects may be the consequence of the injection itself
(e.g. local bleeding and weakening of the tendon) or the injected
substance.
Why it is important to do this review
Achilles tendinopathy is a common condition, often with signifi-
cant functional consequences. A review of the evidence from ran-
domised trials of injection therapies to help inform treatment de-
cisions is warranted in the light of the wide range of available treat-
ments, together with an exponential increase in their use (Kaux
2011). A synthesis of the available evidence may also help to direct
future research in this area.
O B J E C T I V E S
To assess the effects (benefits and harms) of injection therapies for
people with Achilles tendinopathy.
We compared injection therapy versus no treatment, placebo
(sham) treatment, no injection control or other active treatment
(injection or any other treatment including surgery, physiotherapy
or pharmacology). Use of supplementary conservative treatments
across study groups was acceptable.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised and quasi-randomised (using a method of allocating
participants to a treatment that is not strictly random, e.g. by hos-
pital number) controlled clinical trials evaluating injection thera-
pies for Achilles tendinopathy.
Types of participants
People with an investigator-reported diagnosis of Achilles
tendinopathy (or related terminology, e.g. tendinitis).We excluded
trials focusing on the treatment of individuals with systemic con-
ditions (e.g. rheumatoid arthritis and diabetes).
We excluded mixed population trials, including other conditions,
unless the proportion of the population with other conditions was
small and comparable between the intervention groups, or separate
data were available for people with Achilles tendinopathy.
Types of interventions
As described above, there are many different types of injection
therapies. In the first instance, we grouped the therapies by the
following modes of action:
• Injection therapies that cause injury to promote repair
• Injection therapies acting directly on the repair pathway
Ourmain comparisonswere injection therapy versus no treatment,
placebo (sham) treatment or no injection control; and injection
therapy versus other active treatment (such as exercises, orthoses or
surgery). All active treatments were accepted, without exclusion.
Use of supplementary conservative treatments across study groups
was acceptable.
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We also compared different injection therapies, again attempting
to group these by mode of action; and different doses or number
of injections for the same injection therapy.
No single injection therapy is well established or in common use
as a treatment for Achilles tendinopathy. This makes it difficult
to choose a meaningful control intervention when comparing dif-
ferent injection therapies. However, we adopted the following
rules when selecting the control intervention in any comparison:
this will be the older, more traditional therapy (e.g. corticosteroid
would be selected for a comparison of platelet-rich plasma versus
corticosteroid); the less destructive; or the less intensive of the in-
terventions being tested.
Types of outcome measures
The review focused on functional recovery, together with reported
adverse events.
Primary outcomes
• Function measured by a validated patient-reported measure
for Achilles tendinopathy (e.g. VISA-A: an Achilles tendinopathy
specific questionnaire, which contains eight questions that cover
three domains of pain, function and activity. An asymptomatic
person would score 100; the lower the score, the greater the
disability (Robinson 2001)).
• Adverse events:
◦ Serious: e.g. tendon rupture
◦ Non-serious: e.g. post injection discomfort
Secondary outcomes
• Patient-reported quality of life (e.g. EQ-5D, 12-Item Short
Form Health Survey)
• Non-validated patient-reported functional outcomes for
Achilles tendinopathy
• Pain (e.g. as measured by a visual analogue scale (VAS))
• Return to previous level of activity
• Patient rating of acceptability or satisfaction
• Resource use
Some included articles reported multiple measures of pain (e.g.
pain on palpation, pain on walking, pain on resting). Where this
was the case, we accepted the patient-reported pain score during
activity and where no description of the pain score was provided,
we assumed it to refer to pain on activity. All articles used either a
10-point pain scale or a 100-point pain scale. To allow comparison
in data analyses, the authors transformed all 10-point scales to
100-point scales by multiplying the outcomes by 10.
Regarding the outcome of return to previous level of activity, some
articles reported binary yes/no data; others provided further cat-
egories such as returned to sport pain free/returned to sport with
pain/return to some sport/return to no sport. In these instances the
authors recorded all participants that had returned to full sport-
ing activities in one group and collated the remaining responses
into the not returned to sport group. The same scenario presented
with the outcome of patient rating of acceptability/or satisfaction;
again the authors recorded all participants who were satisfied with
their treatment in one group and placed all other responses in the
not satisfied category.
Timing of outcome measurement
Functional outcome scores were reported at multiple time points.
We performed separate analyses representing short (last data point
up to six weeks), medium (last data point up to three months) and
long-term follow-up (last data point after three months) on the
primary outcome measure only. Most secondary outcome mea-
sures (e.g. patient rating of satisfaction and return to sports) were
reported at the final time point only, therefore we performed a
single time point analysis on these outcome measures.
Search methods for identification of studies
Electronic searches
The searches were run in two stages. We initially searched the
Cochrane Bone, Joint and Muscle Trauma Group Specialised
Register (24 February 2014), the Cochrane Central Register of
Controlled Trials (CENTRAL 2014, Issue 1), MEDLINE (1946
to February Week 2 2014), MEDLINE In-Process & Other
Non-Indexed Citations (19 February 2014), EMBASE (1974 to
2014 Week 07), Allied and Complementary Medicine Database
(AMED) (1985 to February 2014), Cumulative Index to Nursing
and Allied Health Literature (CINAHL) (1981 to 28 February
2014) and SPORTDiscus (1985 to 28 February 2014). We also
searched the World Health Organization International Clinical
Trials Registry Platform (WHO ICTRP) and ISRCTN registry
for ongoing and recently completed studies (29 May 2014). We
did not apply any restrictions based on language or publication
status.
In MEDLINE (Ovid Online), we combined a subject-specific
strategy with the sensitivity-maximising version of the Cochrane
Highly Sensitive Search Strategy for identifying randomised trials
(Lefebvre 2011). Search strategies for CENTRAL, MEDLINE,
EMBASE, AMED, CINAHL, SPORTDiscus, theWHO ICTRP
and the ISRCTN registry are shown in Appendix 1.
Subsequently, we conducted a search update on 20 April 2015
of the Group’s Specialised Register, CENTRAL (2015, Issue 3),
MEDLINE, EMBASE, CINAHL, AMED and SPORTDiscus.
Searching other resources
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We searched reference lists of articles retrieved from the electronic
searches and contacted experts in the field for any additional pub-
lished or unpublished articles.
Data collection and analysis
Selection of studies
Two review authors (RK and DM) independently screened search
results for potentially eligible studies, for which we obtained full-
text reports. The same two review authors independently selected
articles for inclusion based on the inclusion criteria listed above.
We resolved any disagreements through discussion, with arbitra-
tion by a third review author (MC) as required.
Data extraction and management
Two review authors (RK and DM) independently extracted data
using a piloted data extraction form. Disagreements were resolved
through discussion,with arbitration by a third review author (MC)
as required. The review statistician (NP), who was independent
from the study selection discussions, collated and managed the
data.
Assessment of risk of bias in included studies
Two review authors (RK and DM) independently assessed the
risk of bias using Cochrane’s ’Risk of bias’ tool (Higgins 2011).
This tool includes the assessment of selection bias (random alloca-
tion and allocation concealment), performance bias (blinding of
participants and personnel), detection bias (blinding of outcome
assessment), attrition bias (incomplete outcome data), reporting
bias (selective reporting) and other sources of bias, such as spon-
sorship from industry. We determined the risk of bias from blind-
ing of subjective and objective outcome measures separately. We
resolved any disagreements through discussion and consensus be-
tween those conducting the review.
Measures of treatment effect
For continuous data, such as functional scores, we calculatedmean
differences with 95% confidence intervals (CI).We planned to use
standardised mean differences where the same outcome measure
was measured using different scoring systems but decided that this
was unnecessary in this version of the review. For dichotomous
outcomes, such as adverse events, we calculated risk ratios with
95% CI.
Unit of analysis issues
We planned to analyse the data by individual participant. We
anticipated that studies would exclude cases of bilateral Achilles
tendinopathy and thus unit of analysis issues associated with a dis-
parity between unit of randomisation (person) and analysis (feet)
would not arise. As this was not the case, we recorded all exceptions
that arose (see Characteristics of included studies). However, the
number of participants with cases of bilateral Achilles tendinopa-
thy included in such studies constituted a very small number over-
all and, as this group of patients could not be separated from the
unilateral cases, we did not conduct sensitivity analysis.
We anticipated simple parallel-group designs, which was the case.
However, in the unlikely event that future trials report cross-over
designs, we intend to analyse only the first phase of the results.
Dealing with missing data
Where thereweremissingdata for binary outcomes, we categorised
them as failures, providing an overall conservative analysis. For
continuous data, we analysed data available and explored the effect
of missing data through sensitivity analyses as appropriate.
We endeavoured to acquire missing data directly from the study
authors. Finally, where standard deviations were not available, we
calculated these from exact P values, CIs, or standard errors. If
it was not possible to calculate the standard deviations, then we
imputed them in cases where standard deviations for the same
outcome measure at the same outcome time point were available
from other studies in the review.
Assessment of heterogeneity
We assessed statistical heterogeneity between studies by visual in-
spection of the overlap of the CIs on the forest plots, and consider-
ation of the Chi² test (P value < 0.1 was interpreted as significant
heterogeneity) and the I² statistic. We interpreted the I² results as
suggested in Higgins 2011: 0% to 40% might not be important,
30% to 60% may represent moderate heterogeneity, 50% to 90%
may represent substantial heterogeneity and 75% to 100% may
represent considerable (very substantial) heterogeneity.
Assessment of reporting biases
Where at least 10 studies contributed data to a meta-analysis,
we planned to generate a funnel plot to explore the potential for
publication bias.
Data synthesis
We pooled results of comparable groups of trials using both fixed-
effect and random-effects models. The choice of the model to re-
port was guided by a careful consideration of the extent of hetero-
geneity and whether it could be explained, in addition to other fac-
tors such as the number and size of studies. If there was substantial
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unexplained heterogeneity (I² > 75%) we considered whether we
should still perform a meta-analysis but instead present a narrative
description.
Subgroup analysis and investigation of heterogeneity
Our primary planned subgroup analysis was by mode of action.
We also planned subgroup analysis for the following groups.
• Insertional versus mid substance tendinopathy
• Athletes versus non-athletes
• Smokers versus non-smokers
• Aged over 65 versus aged 65 years or younger
We planned to investigate whether the results of subgroups were
significantly different by inspecting the overlap of CIs and per-
forming the test for subgroup differences available in ReviewMan-
ager 5 (RevMan 2014). If the heterogeneity statistic was large and
indicated that one or more of the studies was a clear outlier, then
we planned to conduct a meta-analysis with and without the out-
liers and document all such decisions. It was also likely that the
actual substance injected may be a key determinant of outcome
and great source of heterogeneity. Therefore we also planned to
explore clinical heterogeneity according to the substance injected.
Sensitivity analysis
When appropriate we performed sensitivity analyses to examine
various aspects of the trial and review methodology. This included
the effects of missing data (see Dealing with missing data); results
at different time points (seeTypes of outcomemeasures); including
trials at high or unclear risk of bias (see Assessment of risk of bias
in included studies); the selection of a statistical model for pooling
(see Assessment of heterogeneity); and including and excluding
study outliers.
’Summary of findings’ tables
We prepared a ’Summary of findings’ table for the main compar-
ison. We used the GRADE approach to assess the quality of ev-
idence related to each of the key outcomes listed in the Types of
outcome measures (Chapter 12.2, Higgins 2011).
R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
Results of the search
From the results of our first search (run between February 2014
andMay 2014), we screened a total of 677 records from the follow-
ing databases: Cochrane Bone, Joint and Muscle Trauma Group
Specialised Register (37 records); CENTRAL (33), MEDLINE
(134), EMBASE (93), AMED (62), CINAHL (148), SPORTDis-
cus (56), the WHO ICTRP (95) and Current Controlled Trials
(19). There were no potentially eligible studies from other sources.
From our subsequent search update on 20 April 2015 of the
Group’s Specialised Register, CENTRAL,MEDLINE, EMBASE,
CINAHL, AMED and SPORTDiscus, we screened a total of 97
records. A trial registration document was also identified for an
included study (Kearney 2013).
The search identified a total of 23 articles for potential inclusion
andfive registered studies, forwhichwe obtained full reportswhere
possible. Upon study selection, 21 articles were included in 18
studies (Alfredson 2005; Alfredson 2007; Bell 2013; Brown 2006;
Capasso 1993; Chouchane 1989; DaCruz 1988; De Vos 2010
(published in three articles); Fabbro 2012; Fredberg 2004;Kearney
2013 (published in two articles); Larsen 1987; Obaid 2012;
Pearson 2012; Pforringer 1994; Sundqvist 1987; Willberg 2008;
Yelland 2011). We excluded one article (Ferrero 2012), four reg-
istered studies were ongoing (NCT01343836; NCT01954108;
ISRCTN85334402; NCT01583504), and one further registered
study (EUCTR2010-020513-87), and one study reported only as
a conference abstract (Petrella 2013), await classification. Aflowdi-
agram summarising the study selection process is shown in Figure
1.
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Figure 1. Study flow diagram
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Included studies
All included studies were full reports (not abstracts). For further
details, please see the Characteristics of included studies.
Design and comparisons
We included 18 randomised controlled trials evaluating injection
therapies for Achilles tendinopathy published between 1987 and
2013. Sixteen studies had two groups. The remaining two studies
were three-arm randomised controlled trials, each contributing
data to two of the three comparisons tested by the included trials
(Fabbro 2012; Yelland 2011).
Fifteen trials (600 participants) compared an injection therapy
with a placebo injection or no injection control (Alfredson 2005;
Bell 2013; Brown 2006; Capasso 1993; Chouchane 1989;DaCruz
1988; De Vos 2010; Fabbro 2012; Fredberg 2004; Larsen 1987;
Obaid 2012; Pearson 2012; Pforringer 1994; Sundqvist 1987;
Yelland 2011). Two of these compared injections that cause injury
to promote repair to a placebo injection or no injection control
(49 participants in total) (Alfredson 2005; Yelland 2011), with
the remainder comparing injections that act directly on the repair
pathway.
In the second comparison, four studies (105 participants) com-
pared an injection therapy with an active treatment (Alfredson
2007; Fabbro 2012; Kearney 2013; Yelland 2011). Two studies
tested injury-causing agents (Alfredson 2007; Yelland 2011), and
the other two studies tested direct repair agents (Fabbro 2012;
Kearney 2013). The active treatments were surgery (Alfredson
2007), eccentric loading exercises (Kearney 2013; Yelland 2011),
and dry needling (Fabbro 2012).
In a third comparison, one study with 48 participants compared
two different concentrations (high versus low dose) of the same
injection (polidocanol) (Willberg 2008).
Setting
Studies were conducted within sports medicine clinics (Alfredson
2005; Alfredson 2007; Bell 2013; De Vos 2010; Fredberg 2004;
Pearson 2012;Willberg 2008), private practices (Brown 2006), ac-
cident and emergency departments (DaCruz 1988), orthopaedic
departments (Kearney 2013; Obaid 2012; Pforringer 1994;
Sundqvist 1987), primary care centres (Yelland 2011), and occu-
pational medical centres (Larsen 1987), and not stated in three
(Capasso 1993; Chouchane 1989; Fabbro 2012). All but Yelland
2011 were conducted in single centres.
Four trials were completed in Sweden (Alfredson 2005; Alfredson
2007; Sundqvist 1987; Willberg 2008), four in Australasia (Bell
2013; Brown 2006; Pearson 2012; Yelland 2011), three in the UK
(DaCruz 1988; Kearney 2013; Obaid 2012), two in Denmark
(Fredberg 2004; Larsen 1987), one in the Netherlands (De Vos
2010), one in France (Chouchane 1989), and one in Germany
(Pforringer 1994), and the country was not stated in two (Capasso
1993; Fabbro 2012).
Six included articles received funding to complete the trials. Indus-
try sources of funding were: Biomet Biologics LLC, which funded
De Vos 2010; Innovacell, which funded Obaid 2012, and Leo
Pharmaceutical Products, which funded Larsen 1987. Public or
profession-based sources of funding were cited in Kearney 2013
(Chartered Society of Physiotherapy), Willberg 2008 (Swedish
Research Council for Sports), and Yelland 2011 (Musculoskeletal
Research Foundation of Australia, the Australian Podiatry Educa-
tion and Research Foundation and the Griffith University Office
of Research).
Participants
A total of 732 participants were included in the 18 included trials.
Study samples ranged from 20 (Alfredson 2005; Alfredson 2007;
Kearney 2013; Larsen 1987) to 97 (Capasso 1993).
The mean age of the participants in the individual trials ranged
from 20 years (Larsen 1987) to 50 years (Alfredson 2005; Pearson
2012; Willberg 2008). Of the 17 trials reporting on gender,
11 reported a higher ratio of male to female participants (Bell
2013; Brown 2006; Capasso 1993; Chouchane 1989; DaCruz
1988; Fabbro 2012; Fredberg 2004; Larsen 1987; Obaid 2012;
Sundqvist 1987;Willberg 2008). Seven trials exclusively evaluated
injection therapies in recreational/professional athletes (Capasso
1993; Chouchane 1989; Fabbro 2012; Fredberg 2004; Larsen
1987; Pforringer 1994; Sundqvist 1987). None of the 18 trials
recorded the smoking status of included patients.
Eight trials included participants with bilateral symptoms (Brown
2006; DaCruz 1988; Kearney 2013; Larsen 1987; Obaid 2012;
Pearson 2012; Willberg 2008; Yelland 2011). Of these, four trials
explicitly randomised each Achilles tendon as a separate unit (i.e.
one patient was randomised twice for each tendon) (Brown 2006;
DaCruz 1988; Obaid 2012; Pearson 2012), and the remaining
four trials seemed to have randomised the patient as one unit
(i.e. one patient was randomised once for both tendons). Only
one study described the inclusion of participants with pain at the
insertion of the Achilles tendon (Capasso 1993). The remaining
studies all assessed mid portion tendinopathy.
Interventions
The following injection therapies that cause injury or disrupting
vascular ingrowth to promote repair activity were evaluated in the
included studies:
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• Polidocanol: Alfredson 2005; Alfredson 2007; Willberg
2008
• Prolotherapy: Yelland 2011
The following injection therapies acting directly on the repair
pathway were evaluated in the included studies:
• Autologous blood: Bell 2013; Pearson 2012
• Platelet-rich plasma: De Vos 2010; Kearney 2013
• Deproteinised haemodialysate: Pforringer 1994
• Aprotinin: Brown 2006; Capasso 1993
• Polysulphated glycosaminoglycan: Larsen 1987; Sundqvist
1987
• Corticosteroid: Chouchane 1989; DaCruz 1988; Fabbro
2012; Fredberg 2004
• Skin derived fibroblasts: Obaid 2012
Outcomes
This review considered two primary outcome measures, function
measured by a validated patient-reported measure and adverse
events. Of the 18 trials, seven reported the VISA-A (Bell 2013;
Brown 2006; De Vos 2010; Kearney 2013; Pearson 2012; Yelland
2011; Obaid 2012), and all but Pforringer 1994 reported adverse
events. This review also considered the following secondary out-
come measures, which were reported by the following studies:
• Patient-reported quality of life: Kearney 2013
• Non-validated patient-reported outcomes: Brown 2006;
Pforringer 1994
• Pain: Alfredson 2005; Alfredson 2007; Chouchane 1989;
DaCruz 1988; Fabbro 2012; Fredberg 2004; Larsen 1987;
Obaid 2012; Pforringer 1994; Willberg 2008; Yelland 2011
• Return to previous activities: Bell 2013; Brown 2006;
Capasso 1993; DaCruz 1988; De Vos 2010; Pforringer 1994
• Other adverse events: reported by all except Pforringer 1994
• Patient rating of satisfaction: Alfredson 2005; Alfredson
2007; Bell 2013; De Vos 2010; Willberg 2008; Yelland 2011
• Resource use: Fabbro 2012; Yelland 2011
Excluded studies
See Characteristics of excluded studies.
Ferrero 2012 evaluated the effectiveness of platelet-rich plasma in
chronic Achilles tendinopathy but, on further analysis, proved not
to be a randomised controlled trial andwas subsequently excluded.
Ongoing studies
See Characteristics of ongoing studies.
We
identified four ongoing studies (NCT01343836;NCT01954108;
ISRCTN85334402; NCT01583504). These studies include eval-
uation of autologous tenocyte implantation, hyaluronan, cell ther-
apy based on PRP and high-volume saline injections.
Studies awaiting classification
See Characteristics of studies awaiting classification.
Two studies are awaiting classification (EUCTR2010-020513-87;
Petrella 2013). We were unable to determine the status or ob-
tain further information on EUCTR2010-020513-87, which is
reported only in a trial registrationdocument. Petrella 2013,which
compares hyaluronan versus placebo injection in 35 people with
chronic Achilles tendinopathy, is currently insufficiently reported
in a conference abstract only.
Risk of bias in included studies
See Characteristics of included studies and Figure 2.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each study.
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Figure 2 highlights the variability amongst the articles regarding
reporting of key methodological considerations. In particular, tri-
als reported up to 1994 consistently lacked sufficient detailed re-
porting to make valid judgements on several risk of bias domains.
Allocation
Eight studies did not describe the random sequence generation
(Capasso 1993; Chouchane 1989; DaCruz 1988; Fabbro 2012;
Fredberg 2004; Larsen 1987; Pearson 2012; Pforringer 1994).
The 10 remaining studies all used methods describing a random
component in the sequence. Only seven of these 10 also reported
adequate concealment of allocation, including methods of central
randomisation (Kearney 2013; Yelland 2011) and sealed, opaque
envelopes (Alfredson 2005; Alfredson 2007; Bell 2013; De Vos
2010; Willberg 2008). We judged these seven as being at low risk
of selection bias. We judged one study at high risk of bias because
participants could foresee their allocation (Pearson 2012).
Blinding
Six of the trials reported blinding of participants and personnel and
outcome assessment (Alfredson 2005; Bell 2013; Brown 2006; De
Vos 2010; Fredberg 2004; Willberg 2008), and we scored these at
low risk of performance and detection bias. Seven studies did not
describe this component in theirmethods section (Alfredson 2005;
Capasso 1993; Chouchane 1989; DaCruz 1988; Fabbro 2012;
Larsen 1987; Sundqvist 1987). Three studies reported that there
was no blinding of participants, personnel or outcome assessment (
Kearney 2013; Pearson 2012; Yelland2011).Obaid 2012 reported
blinding of the outcome measure assessment only and Pforringer
1994 reported blinding of the participants and personnel only.
We judged all four trials comparing injection therapy versus an
active treatment (Alfredson 2007; Fabbro 2012; Kearney 2013;
Yelland 2011) and Pearson 2012 at high risk of performance bias.
We judged only Kearney 2013 to be at high risk of detection bias.
Incomplete outcome data
Alfredson 2005; Alfredson 2007; Bell 2013; Capasso 1993;
Chouchane 1989; Fabbro 2012; Larsen 1987; Pforringer 1994;
Sundqvist 1987 and Willberg 2008 did not discuss missing data
or its handling in their final results. We judged Bell 2013; De Vos
2010; Fredberg 2004; Kearney 2013; Obaid 2012; Pearson 2012
and Yelland 2011 as being a low risk as they either reported no
missing data or reasons for data being missing with appropriate
analysis methods. This is in contrast to DaCruz 1988, which we
judged as being at high risk of attrition bias.
Selective reporting
Only three studies provided evidence of publication of prior pro-
tocols in trials databases (Bell 2013; De Vos 2010; Kearney 2013).
Other potential sources of bias
We judged six studies as having a high risk of another potential
source of bias. Brown 2006 carried out their study in a private
practice and provided all participants with free treatment and fol-
low-up in the private clinic. The lack of details on randomisation
and absence of an explanation for the imbalance in numbers in the
intervention and control groups of Capasso 1993 mean that we
cannot rule out that data from non-randomised patients were in-
cluded. Fredberg 2004 had a high number of participants crossing
over within the study period. Three were supported with industry
funding (De Vos 2010; Larsen 1987; Obaid 2012).
Effects of interventions
See: Summary of findings for themain comparison Summary of
findings: Injection therapies versus placebo or no injection control
Where available, the primary outcome data (Victorian Institute of
Sport Assessment-Achilles questionnaire (VISA-A)) are presented
for short (last data point up to six weeks), medium (last data point
up to three months) and long-term (last data point after three
months) time points. Where available, the secondary outcome
data are reported at final follow-up for individual trials. We made
an exception for pain scores because of the distribution of these.
The inclusion of 10 studies only occurred in one analysis of adverse
events (Analysis 1.5), however we did not generate a funnel plot
in this case due to the low number of events.
Comparison I: Injection therapies versus placebo
injection or no injection control
Fifteen studies compared injection therapies versus a placebo in-
jection or no injection control (Alfredson 2005; Bell 2013; Brown
2006; Capasso 1993; Chouchane 1989; DaCruz 1988; De Vos
2010; Fabbro 2012; Fredberg 2004; Larsen 1987; Obaid 2012;
Pforringer 1994; Pearson 2012; Sundqvist 1987; Yelland 2011).
We subgrouped these by mode of action. Two studies, which eval-
uated polidocanol and prolotherapy, were in the subgroup of in-
jection therapies (Alfredson 2005; Yelland 2011). The other 13
studies were in the subgroup of injection therapies that act directly
on the repair pathway; these included injection therapies of autol-
ogous blood, platelet-rich plasma, deproteinised haemodialysate,
aprotinin, polysulphated glycosaminoglycan, corticosteroid and
skin-derived fibroblasts). Due to the large range of injection types
and outcomes reported, we did not undertake separate subgroup
analyses by individual injection therapies.
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Primary outcome measures
VISA-A
The VISA-A was reported by five studies at six weeks and three
months (Bell 2013; Brown 2006; De Vos 2010; Pearson 2012;
Yelland 2011; 200 patients) and by three studies beyond three
months (Bell 2013; De Vos 2010; Yelland 2011; 132 patients). At
each time point, we considered heterogeneity to be unimportant
(overall I² below 40% for all time points).
The pooled analysis at all three time points shows that the injec-
tion group is no better than placebo and/or no injection control
(six weeks: mean difference (MD) 0.79, 95% confidence interval
(CI) -4.56 to 6.14; three months: MD -0.94, 95% CI -6.34 to
4.46; after three months: MD 0.14, 95%CI -6.54 to 6.82).When
we divided the data into subgroups of those injections that cause
injury to promote repair (Yelland 2011), and those that act directly
on the repair pathway (Bell 2013; Brown 2006; De Vos 2010;
Pearson 2012), again at no time points did the injection ther-
apy group demonstrate superiority (see Analysis 1.1; Analysis 1.2;
Analysis 1.3). We extracted data for mean scores for Yelland 2011
from a graph and we imputed standard deviations for three trials
(Brown 2006; Pearson 2012; Yelland 2011) from data from sim-
ilar studies. Yelland 2011 presented an intention-to-treat analysis
for the number of participants who had achieved the minimum
clinically important increase of 20 points in VISA-A scores from
baseline over time; this also did not show a difference between the
two groups at any of the three follow-up times (see Analysis 1.4).
Obaid 2012 reported VISA-A at six weeks, three months and
six months. However, the data reported were median and ranges
and therefore we did not include them in the pooled analysis.
At each time point the VISA-A results for the 12 patients in the
interventional arm were 50 (range 15 to 85), 50 (range 30 to 90)
and 80 (range 35 to 90). For the control arm the results were 35
(range 10 to 50), 36 (range 20 to 55) and 34 (range 22 to 58).
Adverse events
Adverse events were reported by all but one study (Pforringer
1994). Data split by injection therapy and control were available
for 13 studies (14/243 versus 12/206; risk ratio (RR) 0.97, 95%
CI 0.50 to 1.89; seeAnalysis 1.5). The overall I² indicated insignif-
icant heterogeneity (less than 40%), with no evidence of subgroup
differences based on mode of action. Adverse events in the injec-
tion groups included reports of increasedmild pain (Brown 2006),
slight burning (Capasso 1993), slight skin reaction (Chouchane
1989), tendon rupture (Fredberg 2004), and bruising at injection
sites (Larsen 1987). The tendon rupture was the only serious ad-
verse event and occurred during a trial of local steroid injection.
Adverse events in the placebo/no injection control included one
calf tear (Yelland 2011), mild pain (Brown 2006), and slight skin
reaction (Chouchane 1989). Fabbro 2012, which compared injec-
tion therapy plus dry needling versus dry needling only, reported
only three minor complications, such as “mild pain after the pro-
cedure” but did not identify the group(s) in which these occurred.
Secondary outcome measures
Patient-reported quality of life
Not reported.
Non-validated patient-reported functional outcomes
Not reported.
Pain (visual analogue scale (VAS) 0 to 100: worst pain)
Seven studies reported pain outcomes, totalling 219 participants
(Alfredson 2005; Chouchane 1989; Fabbro 2012; Fredberg 2004;
Larsen 1987; Pforringer 1994; Yelland 2011). Of these we sub-
grouped Alfredson 2005 and Yelland 2011 into injections that
cause injury to promote repair (47 participants) and we sub-
grouped the remaining studies into injections that act directly on
the repair pathway (172 participants). We extracted data for mean
scores from graphs for five studies (Fabbro 2012; Fredberg 2004;
Larsen 1987; Pforringer 1994; Yelland 2011), and we imputed
standard deviations for these five trials from data from similar
studies. Pain results for periods up to three months are presented
in Analysis 1.6. The individual trial and pooled results are all in
favour of the injection group (MD -22.94, 95% CI -37.53 to -
8.36), but there was very significant heterogeneity in the results
for the injection therapies that act directly on the repair pathway
(I² = 86%). DaCruz 1988 also reported a pain score within their
trial; however, the article contained insufficient data to report any
summary statistics.
Three trials, which did not include cross-over to the active in-
tervention for participants allocated placebo, reported on longer-
term results (Fabbro 2012; Obaid 2012; Yelland 2011). By 12
months follow-up in Fabbro 2012, the mean VAS pain scores in
both the steroid injection plus dry needling group and the dry
needling group had dropped to zero.Obaid 2012 reportedmedian
and ranges only of 40 (range 30 to 60) for the injection therapy
group and 10 (range 0 to 20) for the placebo group at six months.
Pain scores in Yelland 2011 declined over time in both groups but
to a lesser extent in the exercises only group; the mean pain scores
at 12 months were 12.5 in the prolotherapy plus exercises group
versus 31 in the exercises group.
Return to previous level of activity
Seven studies reported return to sport as an outcome, including
335 participants in total (Bell 2013; Brown 2006; Capasso 1993;
DaCruz 1988; De Vos 2010; Larsen 1987; Pforringer 1994). The
seven studies included six different injection therapies (autologous
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blood, platelet-rich plasma, aprotinin, corticosteroid, heparin and
deproteinised haemodialysate). The pooled data for the number of
participants returning to sport or military training (Larsen 1987)
favour injection therapy (RR 1.39, 95% CI 1.00 to 1.94), but
there is significant and substantial heterogeneity (I² = 65%; see
Analysis 1.7).
Patient rating of acceptability or satisfaction
Four studies reported this outcome (Alfredson 2005; Bell 2013;
De Vos 2010; Yelland 2011; 152 participants). We subgrouped
Alfredson 2005 and Yelland 2011 into injury-causing agents (47
participants) and we subgrouped Bell 2013 and De Vos 2010 into
direct repair agents (105 participants).
The pooled analysis shows no significant result (53/76 versus 48/
76 were satisfied; RR 1.05, 95% CI 0.76 to 1.47), with no indi-
cation of subgroup differences (I² = 0%) (Analysis 1.8).
Resource use
Fabbro 2012 reported the cost of the intervention to be EUR 70;
no further data were presented. Yelland 2011 also reported the cost
of the interventions only, reporting the combined injection and
exercise to be AUD 591 and exercise only AUD 400 per patient.
This cost difference was based on the sum of health insurance for
the respective treatments, additional GP and specialist visits, allied
health professional visits, pharmaceutical costs and ’other’ costs.
No other studies discussed resource use.
Comparison II: Injection therapies versus active
treatment
Four studies (105participants in this comparison) compared injec-
tion therapies versus an active treatment (Alfredson 2007; Fabbro
2012; Kearney 2013; Yelland 2011). Two studies tested injury-
causing agents (Alfredson 2007; Yelland 2011), respectively poli-
docanol and prolotherapy, and the other two studies tested di-
rect repair agents (Fabbro 2012; Kearney 2013), respectively cor-
ticosteroid and platelet-rich plasma. The active treatments were
surgery (Alfredson 2007), eccentric loading exercises (Kearney
2013; Yelland 2011), and dry needling (Fabbro 2012). Given the
disparity between the active treatments, we have presented the re-
sults grouped by comparison.
Primary outcome measures
VISA-A (0 to 100: best score)
This outcome was reported by Kearney 2013 and Yelland 2011
at each time point. Although favouring injection therapy, none
of the differences between the two groups in Kearney 2013 were
significant at any of the three time points (see Analysis 2.1). Mean
scores for Yelland 2011, extracted from a graph, showed little dif-
ference between the two groups at three time points: 71 for injec-
tion therapy versus 70 for exercises (six weeks); 81 versus 80 (three
months); and 86 versus 82 (12 months). Yelland 2011 presented
an intention-to-treat analysis for the number of participants who
had achieved the minimum clinically important increase of 20
points in VISA-A scores from baseline over time; this also did not
show a difference between the two groups at any of the three fol-
low-up times (see Analysis 2.2).
Adverse events
All four studies (102 participants) reported on adverse events.
Alfredson 2007 reported one deep wound infection in the sur-
gical group, Kearney 2013 reported there were no complications
in either group and Yelland 2011 reported one calf tear in their
eccentric loading exercises group (see Analysis 2.3). Fabbro 2012
reported only three minor complications, such as “mild pain after
the procedure” but did not identify the group(s) in which these
occurred.
Secondary outcome measures
Patient-reported quality of life
This was only reported byKearney 2013, who found no significant
difference in EQ-5D scores (0 to 1: best quality of life) at six
months (MD 0.08, 95% CI -0.25 to 0.41; see Analysis 2.4).
Non-validated patient-reported functional outcomes for
Achilles tendinopathy
Not reported.
Pain (VAS 0 to 10: worst pain)
There were no usable data for Alfredson 2007, who reported pain
outcomes for subgroups only. Mean pain scores were presented
graphically for both Fabbro 2012 and Yelland 2011. By 12months
follow-up in Fabbro 2012, the mean VAS pain score in the steroid
injection therapy group had increased from a low point of less than
0.5 points at 14 days to approximately 5.1 points, while that for
the dry needling group had dropped to zero. Pain scores in Yelland
2011 declined over time in both groups but to a lesser extent in the
exercises group; the mean pain scores at 12 months were 1.25 in
the prolotherapy group versus 3.1 in the exercises group. Yelland
2011 reported that the decreases in pain scores from baseline for
the exercises group “were significantly less by a clinically important
difference than for prolotherapy at 6 months (difference 2.3; 95%
Wald CI 0.3 to 4.4; p=0.028)”.
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Return to previous level of activity
Not reported.
Patient rating of acceptability or satisfaction
Two trials reported patient satisfaction with treatment (Alfredson
2007; Yelland 2011) (see Analysis 2.5). In Alfredson 2007, fewer
(6/10) participants were satisfied with the injection therapy com-
pared with those in the surgery group (10/10): RR 0.62, 95% CI
0.37 to 1.03. Yelland 2011 found slightly more satisfied partici-
pants given injection therapy compared with those given eccentric
exercises: 9/13 versus 7/13; RR 1.29, 95% CI 0.69 to 2.39.
Resource use
No studies conducted a health economic analysis. However,
Yelland 2011 reported that prolotherapy cost an additional AUD
90 in total compared with the eccentric exercises. This cost differ-
ence was based on the sum of health insurance for the respective
treatments, additional GP and specialist visits, allied health pro-
fessional visits, pharmaceutical costs and ’other’ costs.
Comparison III: High-dose versus low-dose injection
therapy
One study compared high-dose (10 mg/ml) with low-dose (5 mg/
ml) polidocanol in 48 participants with 52 affected tendons (
Willberg 2008). No adverse events were reported in either trial
arm (see Analysis 3.1). There was no difference between the two
doses in the pain scores after one to three treatments (treatments
were six to eight weeks apart) measured on a VAS (0 to 100: higher
scores mean worse pain): MD -1.00, 95% CI -17.06 to 15.06; 52
tendons (see Analysis 3.2). Similar numbers of participants were
satisfied with the treatment of their tendon after a maximum of
three treatments (19/26 versus 20/26; RR 0.95, 95% CI 0.69 to
1.30; see Analysis 3.3); all 13 dissatisfied participants accepted the
offer of another injection and all participants were reported as
being ultimately satisfied with their treatment after a maximum
of five injections.
Comparison IV: Injection therapy versus injection
therapy
No studies were included.
Subgroup analyses
There were either insufficient or no available data to conduct
any of the four pre-planned subgroup analyses relating to partic-
ipant characteristics (see Subgroup analysis and investigation of
heterogeneity). Of particular note is that only Capasso 1993 in-
cluded participants with insertional tendinopathy.
D I S C U S S I O N
Summary of main results
This review, which covers injection therapies for Achilles
tendinopathy, includes 18 small trials involving a total of 732
participants. Sixteen trials had two groups. The other two trials
had three groups, and contributed data to two of the three main
comparisons tested by the included trials. Seven of the included
trials reported the primary outcome measure of interest, Victo-
rian Institute of Sport Assessment-Achilles questionnaire (VISA-
A). These trials were all published from 2006 onwards, which
probably reflects the timeline between the outcome measure de-
velopment (Robinson 2001) and uptake in clinical trials. All but
one trial reported on adverse events. The 18 studies evaluated
nine different injection therapies, two of which were injury-caus-
ing agents (polidocanol, prolotherapy), and the other seven of
which were direct repair agents (autologous blood, platelet-rich
plasma, deproteinised haemodialysate, aprotinin, polysulphated
glycosaminoglycan, corticosteroid and skin-derived fibroblasts).
Consistent with our protocol and given the small number of trials
and limitation of the outcome data, we subgrouped injection ther-
apy by mode of action rather than different injection therapies.
Fifteen trials compared one of nine different injection therapies
with a placebo injection or no injection control, four trials com-
pared an injection therapy with active treatment, and one trial
compared two different concentrations of the same injection. No
trials compared different injection therapies.
Comparison I: Injection therapies versus placebo
injection or no injection control
The findings for this comparison, tested by 15 trials, are sum-
marised in Summary of findings for the main comparison. There
is low quality evidence of a lack of clinically important differences
in VISA-A scores between injection therapy and control groups
at six weeks (200 participants, five trials), three months (189 par-
ticipants, five trials) or between six and 12 months (132 partici-
pants, three trials). Very low quality evidence showed little differ-
ence between the two groups in adverse events (449 participants,
13 trials), most of which were minor and short-lasting. The only
major adverse event in the injection therapy group was an Achilles
tendon rupture, which happened in a trial testing corticosteroid
injections. There was very low quality evidence in favour of the
injection therapy group in short-term (under three months) pain
(219 participants, seven trials) and in return to sports (335 par-
ticipants, seven trials) There was very low quality evidence indi-
cating little difference between groups in patient satisfaction with
treatment (152 participants, four trials). There was insufficient
evidence to conclude on subgroup differences based on mode of
action given that only two trials tested injury-causing agents and
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the clear heterogeneity of the other 13 trials, which tested thera-
pies that act directly on the repair pathway.
The review authors identified three ongoing (or not fully char-
acterized) studies in this category, evaluating autologous tenocyte
implantation, hyaluronan with botulinus toxin, and platelet-rich
plasma. None of these studies is a large multi-centre study that is
likely to provide future definitive evidence on this group of ther-
apies.
Comparison II: Injection therapies versus active
treatment
Four small studies compared an injection therapy versus an active
treatment.While presented together in one section, each trial pro-
vided low or very low quality and generally incomplete evidence
for a different comparison. One trial, Alfredson 2007 with 20 par-
ticipants, comparing an injury-causing agent versus surgery, re-
ported a deepwound infection in the surgery group but found that
all 10 participants in this group were satisfied with their treatment
compared with six of 10 treated with injection therapy. One trial,
Fabbro 2012 with 36 participants, comparing a direct repair agent
versus dry needling, reported three minor adverse events (mild
pain post procedure) but did not identify the treatment group in
which these occurred. It found significantly higher pain scores in
the steroid group compared with the exercise group at 12 months.
One pilot study, Kearney 2013, with 20 participants comparing a
direct repair agent versus eccentric exercises, found no significant
difference between the two interventions in VISA-A scores at six
weeks, and three and six months. The study reported no compli-
cations and minimal between-group difference in quality of life.
One study, Yelland 2011 with 29 participants, comparing an in-
jury-causing agent versus eccentric exercises, found no significant
difference between the two interventions in VISA-A results at six
weeks, and three and 12 months. It reported that one participant
in the eccentric exercise group suffered a calf muscle tear during
sport, and found greater pain in the exercise group at 12 months,
and slightly but not significantly greater patient satisfaction in the
injection group.
We identified one ongoing but small study in this category that is
comparing hyaluronan versus extracorporeal shock wave therapy
(NCT01954108).
Comparison III: High-dose versus low-dose injection
therapy
The evidence from one study with 48 participants (52 tendons)
that compared polidocanol 10 mg/ml versus polidocanol 5 mg/
ml was of very low quality. The trial reported no adverse events,
and no difference in pain or in the numbers of participants who
were satisfied after a maximum of three treatments.
Comparison IV: Injection therapy versus injection
therapy
We included no studies in this category.We identified one ongoing
study that is evaluating high-volume injection therapy. However,
this is a small study that is unlikely to provide definitive evidence.
Overall completeness and applicability of
evidence
The main comparison of this review was evaluated in 600 people
with Achilles tendinopathy by 15 small trials. However, data were
available for the key primary outcome (VISA-A) for a maximum
of only 200 participants in five trials. Exact mean values for final
VISA-A scores could be calculated for only four trials and actual
standard deviations were only available for two trials (106 par-
ticipants). This illustrates the incompleteness of the data for this
review. Although adverse outcome data could be pooled from 13
trials (449 participants), the rarity of serious adverse events means
that a far greater population size would be required to appreciate a
true picture. Follow-up was too short in several trials, in particular
to measure outcomes such as recurrence. This is largely reflective
of clinical practice, whereby after a period of six months it would
not be unreasonable to trial a different treatment modality if the
one initially administered was ineffective.
We kept the inclusion criteria for this review broad in an attempt
to ensure that the final results were applicable to everyday practice.
However, seven studies evaluated injection therapies, all acting di-
rectly on the repair pathway, exclusively in an athletic population
(Capasso 1993; Chouchane 1989; Fabbro 2012; Fredberg 2004;
Larsen 1987; Pforringer 1994; Sundqvist 1987). This finding is in
keeping with the study settings, of which just under half took place
in sports medicine clinics. Furthermore, the mean age of partici-
pants in all 18 trials was under 50 years; therefore the applicability
of the results to an older non-athletic group in a secondary or pri-
mary care setting is limited. The studies, however, were conducted
across several countries (Australasia, Denmark, France, Germany,
the Netherlands, Sweden, UK) and therefore not specific to one
particular healthcare system.
Although the data were insufficient to draw any conclusion on
the relative effects of injection therapies that involve injury-caus-
ing agents and those that involve direct repair agents, it should be
noted that the majority of the evidence was for injection thera-
pies that act directly on the repair pathway. The results of these
were often heterogeneous, potentially due to the range of injection
treatments. There is, however, insufficient evidence from different
injection therapies to draw any conclusions on individual thera-
pies. Nonetheless, it can be observed that the sole serious event, a
tendon rupture, occurred after injection therapy involving a cor-
ticosteroid.
When interpreting the outcome measures it is important to con-
sider that, of these, only the VISA-A is a validated score with clin-
ically meaningful interpretation (Robinson 2001). The definition
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and interpretation of pain, return to sports and patient satisfaction
scores are more difficult to interpret clinically due to the differ-
ences in scoring systems and absolute definitions. For example,
some of the included articles reported return to sport as a binary
yes/no response; others further sub-categorised the responses to
return to sport without pain and return to sport with pain.
Quality of the evidence
The risk of bias amongst all trials up to 1994 was unclear or high.
It is encouraging that the subsequent series of trials between 2004
and 2013 are of higher quality, as shown in Figure 2. Despite the
improvement in quality, only Bell 2013 scored positively on all
parameters. It is also important to note that, although themajority
of studies were placebo-controlled randomised controlled trials,
considered to be the gold standard in trial design, the majority
failed to describe blinding procedures. Furthermore, the largest
trial samplewas 97 (Capasso 1993), and so this review is comprised
of trials with predominantly small sample sizes.
The review is also limited by the large range of different injections
evaluated. Although the authors have attempted to group the in-
jections by comparator arm and mode of action, this introduces
clinical heterogeneity. There was also large statistical heterogeneity
amongst some analyses, which may be due in part to the prob-
lems highlighted above with inconsistent definitions of outcome
measures and timing of outcome reporting. In these cases we re-
moved clear outliers for further sensitivity analysis. Consequently,
the heterogeneity and quality of the 18 included studies precludes
the drawing of robust conclusions.
We assessed the evidence for the outcomes of the comparison of
injection therapy versus placebo or no injection control tested by
15 small studies as being either of low quality (VISA-A results)
or very low quality (adverse events, pain, return to sports, pa-
tient satisfaction); see details in Summary of findings for the main
comparison. As well as for limitations in study design and imple-
mentation, we downgraded the evidence further for imprecision,
indirectness and inconsistency. As noted in Summary of findings
for the main comparison, the interpretation of ’low quality’ evi-
dence is that “Further research is very likely to have an important
impact on our confidence in the estimate of effect and is likely
to change the estimate”. That of very low quality evidence is that
“We are very uncertain about the estimate”.
We assessed the evidence for all the available outcomes from the
four small studies testing four different comparisons in the injec-
tion therapy versus active treatment category as being of very low
quality. We downgraded the evidence one level for study limita-
tions, including performance bias from lack of blinding of care
providers, and two levels for serious imprecision given the few data
available for each comparison.
We assessed the evidence for the study comparing two doses of
the same injection therapy as being of very low quality. We down-
graded it two levels for indirectness of evidence and one for impre-
cision of results: only one study included, at a single centre, using
a single operator to administer one type of injection therapy not
in common use in a small study sample.
Potential biases in the review process
We have searched the published literature using a comprehensive
search strategy, as outlined in Appendix 1. We are therefore con-
fident that we have not missed any large body of definitive evi-
dence that would change clinical practice. However, it is possible
that we have failed to identify trials, particularly those of non-
English publication, abstract only publications or those not pub-
lished, e.g. commercially sponsored with negative results. Addi-
tionally, although we searched trial registries, it is likely that we
have missed ongoing studies that have not been registered. Where
data were missing we made efforts to contact authors. We also
strived to make the most of the data that were available, such as
by reading mean VISA-A and pain scores off graphs and imputing
missing standard deviations. However, the validity of these data is
questionable and we downgraded the quality of the evidence with
this in mind.
Agreements and disagreements with other
studies or reviews
Our results are consistent with previous systematic reviews that
have also discussed the large range of injection therapies reporting
inconsistent outcome measures at multiple time points across a
large range of injection types (Coombes 2010; DTB 2012). Nei-
ther of these reviews found sufficient clinical evidence to recom-
mend injection therapies for Achilles tendinopathy.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is insufficient evidence from randomised controlled trials
to draw conclusions on the use of injection therapies for treating
Achilles tendinopathy. Since this review does not add support to
the wider clinical use of injection therapies for Achilles tendinopa-
thy, the use of injection therapies should be considered in research
settings in the first instance to address this lack of evidence.
Implications for research
This review has highlighted a need for definitive research in the
area of injection therapies for Achilles tendinopathy. It has also
highlighted the need for research in primary and secondary care
settings amongst an older non-athletic population in addition to
those who are younger and more active. Discussion in the research
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community, with consumer and other stakeholder input, is re-
quired to prioritise the choice of injection therapies and research
questions. This review has shown that a placebo-controlled/no
injection control trial is largely considered the most appropriate
trial design to answer the question of treatment efficacy of this
intervention. Follow-up of at least six months is required as well
as comprehensive reporting of trial methods and final outcome,
including of final function using validated outcome measures.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alfredson 2005
Methods Randomised controlled trial
Participants Setting: Sports medicine unit, Sweden
Sample: 20 participants, referred from general practitioners, with clinically diagnosed
mid portion Achilles tendinopathy
Characteristics: 9 men and 11 women, mean (range) age 50 years (unknown). Unilateral
tendinopathy only
Interventions In all participants the injectionswere directly into areas of local neo visualisation and after
14 days free activity with full tendon loading was allowed. A maximum of 2 treatments
3 to 6 weeks apart were administered
Intervention: ultrasound and doppler-guided polidocanol (5 mg/ml)
Control: ultrasound and doppler-guided lidocaine hydrochloride (5 mg/ml) and
adrenaline (5 µg/ml)
Outcomes All patients followed up at 3 months
Primary: pain during Achilles tendon loading activities (VAS 0 to 100) and presence or
absence of neo visualisation
Secondary: patent satisfaction with the treatment (interview)
Notes The trial authors describe this as a trial of injection therapy with a substance that has a
sclerosing and an anaesthetic effect versus injection with a substance that has an anaes-
thetic effect only. The comparator was categorised as a control rather than an active
treatment in this trial by the review authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...the patients selected an envelope allocating
themselves to either treatment...”
Comment: the investigators describe a random compo-
nent in the sequence generation process
Allocation concealment (selection bias) Low risk Quote: “...box with 20 opaque envelopes...”
Comment: the investigators’ assignment envelopes were
used with safeguards (e.g. non-opaque)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “...The radiologist...and patients were blinded to
the substance that was injected...”
Comment: blinding of patients and personnel ensured
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Alfredson 2005 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “...The radiologist, who performed all ultrasound
and doppler examinations and the patients were blinded.
..”
Comment: blinding of outcome assessment ensured
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: no missing outcome data reported or dis-
cussed
Selective reporting (reporting bias) Unclear risk Comment: no published protocol available
Other bias Unclear risk Comment: insufficient information presented to assess
whether an important risk of bias exists
Alfredson 2007
Methods Randomised controlled trial
Participants Setting: Sports medicine unit, Sweden
Sample: 20 participants, referred from general practitioners, with clinically diagnosed
mid portion Achilles tendinopathy
Characteristics: 9 men and 11 women, mean (range) 46 years (unknown). Unilateral
tendinopathy only
Interventions Intervention: ultrasound and doppler-guided polidocanol (10 mg/ml) injected into areas
of local neovascularisation. After 14 days free activity with full tendon loading was
allowed. Additional treatments offered if pain persisted
Control: surgical treatment. Achilles tendon released from ventral soft tissue, followed
by haemostasis using diathermia. After 14 days free activity with full tendon loading was
allowed
Outcomes All patients were followed up at 3 and 6 months
Primary: pain during Achilles tendon loading activity (VAS 0 to 100)
Secondary: patient-reported satisfaction (satisfied or not satisfied)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...the patients selected an envelope allocating
themselves to either treatment...”
Comment: the investigators describe a random compo-
nent in the sequence generation process
Allocation concealment (selection bias) Low risk Quote: “...box with 20 opaque envelopes...”
Comment: the investigators’ assignment envelopes were
used with safeguards
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Alfredson 2007 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: investigators do not report blinding proce-
dures but blinding of care providers is unlikely given the
interventions under comparison
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: investigators do not report blinding proce-
dures
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: no missing outcome data reported or dis-
cussed
Selective reporting (reporting bias) Unclear risk Comment: no published protocol available
Other bias Unclear risk Comment: insufficient information presented to assess
whether an important risk of bias exists
Bell 2013
Methods Randomised controlled trial
Participants Setting: Sports medicine clinic, New Zealand
Sample: 53 participants with clinically diagnosed mid portion Achilles tendinopathy.
Unilateral tendinopathy only
Characteristics: 28 men and 25 women mean age (SD) 51.2 years (10.6) in the inter-
vention group and 47.2 (9.7) in the control group
Interventions All participants received 2 unguided peritendinous injections at the site of maximal
tenderness at baseline and 1 month later. All had 3 ml of their own blood taken from
the antecubital fossa. All had a standardised injection through a single puncture site. All
completed a 12-week eccentric loading programme following the injection
Intervention: patients received the 3 ml of blood
Control: no substance injected (’dry needling’, no anaesthesia)
Outcomes All patients were followed up at 1, 2, 3 and 6 months
Primary: VISA-A
Secondary: 6-point Likert score at final follow-up to assess perceived rehabilitation;
return to sport and adherence to eccentric loading programme
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...each participant underwent simple randomi-
sation into one of the two groups by selecting sealed en-
velope from the box...”
Comment: the investigators describe a random compo-
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Bell 2013 (Continued)
nent in the sequence generation process
Allocation concealment (selection bias) Low risk Quote: “...equal numbers of opaque envelopes...”
Comment: the investigators’ assignment envelopes were
used with safeguards
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “...participants lay prone with a screen over their
legs to block any view of the intervention taking place...
participants completed the questionnaire under supervi-
sion from the blinded assessor...”
Comment: blinding of participants and study personnel
ensured
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “...participants completed the questionnaire un-
der supervision from the blinded assessor...”
Comment: blinding of outcome assessment ensured
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “...we used intention to treat analysis via last ob-
servation carried forward for the three participants lost
to follow up, with their final recorded outcome being
brought forward for the remaining missed data points...
”
Comment: missing data have been imputed using appro-
priate methods
Selective reporting (reporting bias) Low risk The study protocol is available and all of the study’s pre-
specified outcomes have been reported
Other bias Low risk None
Brown 2006
Methods Randomised controlled trial
Participants Setting: private practice, Australia
Sample: 26 participants with clinically diagnosed mid portion Achilles tendinopathy.
Bilateral tendinopathy included: 33 tendons
Characteristics: 17 men and 9 women, mean age (range) 46 years (30 to 73)
Interventions All patients received 3 injections 1 week apart
Intervention: 12-week eccentric loading programme and aprotinin injection (3 ml apro-
tinin and 1 ml xylocaine 1%)
Control: 12-week eccentric loading programme and placebo injection (3 ml saline and
1 ml xylocaine)
Outcomes All patients were followed up at 2 weeks, 1 month, 3 month and 12 months
Primary: VISA-A
Secondary: patient rating of improvement and return to full activities
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Brown 2006 (Continued)
Notes Achilles tendinopathy randomised as per tendon; as evidenced: “This patient received
bilateral injections (one aprotinin injection and one placebo injection).”
Data analysis: SD imputed for VISA-A scores from other trials in the same analysis
category
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...allocation of patients was organised by AH,
using a random number selection...”
Comment: the investigators describe a random compo-
nent in the sequence generation process
Allocation concealment (selection bias) Unclear risk Comment: the investigators do not report the method of
allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “...patients and examiners were blinded to their
allocation..”
Comment: blinding of patients and study personnel en-
sured
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “...the evaluating authors were blinded to the
treatment groups...”
Comment: blinding of outcome assessment ensured
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: no missing outcome data reported or dis-
cussed
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement of low risk
or high risk
Other bias High risk Patients who chose to enrol received free treatment and
follow-up in the private clinic
Capasso 1993
Methods Randomised controlled trial
Participants Setting: not stated
Sample: 97 participants, professional and amateur sports people with mid portion and
insertional Achilles tendinopathy. Unilateral tendinopathy only
Characteristics: 65 men and 32 women, age not reported
Interventions All patients were advised to rest throughout the treatment period. All patients had
between 4 and 6 injections
Intervention: 2.5 ml of aprotinin
Control: apyrogenic double distilled water
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Capasso 1993 (Continued)
Outcomes No time points described
Patient satisfaction, symptoms (spontaneous or provoked pain, local swelling, limitation
of function), ultrasound or thermography, time to return to sports
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: no description
Allocation concealment (selection bias) Unclear risk Comment: no description
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: the authors describe this as a placebo-con-
trolled trial, but no description of blinding procedures is
provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: no description
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: no description of missing data or how this
was handled
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement of low risk
or high risk
Other bias High risk Comment: the trial is poorly reported and only described
in outline. It has not been possible to exclude other types
of bias from this report and the lack of any details of the
randomisation method and the unexplained imbalance
in treatment allocation could include the strong possibil-
ity that some non-randomised participants treated with
aprotinin were included in the analysis
Chouchane 1989
Methods Randomised controlled trial
Participants Setting: only country stated, France
Sample: 32 participants with tendinopathy secondary to sports overuse. Unilateral
tendinopathy only
Characteristics: 20 men and 12 women, average age 38 years
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Chouchane 1989 (Continued)
Interventions All patients administered 2 injections, twice a day for 7 days
Intervention: 2 ml percutalgine
Control: placebo (substance not stated)
Outcomes All outcomes at 7 days
Local pain on VAS (0 to 10), pain during mobilisation, calf raises, overall effectiveness
was assessed by a doctor on a 4-point scale and adverse effects
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: no description
Allocation concealment (selection bias) Unclear risk Comment: no description
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: no description
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: no description
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: no description
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement of low risk
or high risk
Other bias Unclear risk Comment: the trial is poorly reported and only described
in outline. It has not been possible to exclude other types
of bias from this report
DaCruz 1988
Methods Randomised controlled trial
Participants Setting: Accident and Emergency Department, UK
Sample: 36 participants, presenting to an accident and emergency department, with
clinically diagnosed mid portion Achilles tendinopathy
Characteristics: 18 men and 10 women (8 unknown), mean (range) 28 years (22 to 46)
. Bilateral tendinopathy included (6 of 28 in analysis)
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DaCruz 1988 (Continued)
Interventions All patients received a 4-week period of physiotherapy including ice application, thera-
peutic ultrasound and felt heel inserts
Intervention: 40 mg methyl prednisolone acetate in 1 ml of bupivacaine hydrochloride
0.25%
Control: 2 ml of 0.25% bupivacaine hydrochloride alone
Outcomes All patients were followed up at 3 weeks, 6 weeks and 12 weeks
Outcomes: 10 cm linear analogue scale in response to the question ’How bad is your
pain when it is at its worse?’; tendon thickness; activity level score; tenderness
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “...all patients were randomised...”
Comment: insufficient information about the sequence
generation to permit judgement of low or high risk
Allocation concealment (selection bias) Unclear risk Quote: “...all patients were randomised...”
Comment: method of concealment is not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “...follow up was conducted on a double blind
basis...”
Comment: no further information is provided regarding
how or who was blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “...follow up was conducted on a double blind
basis...”
Comment: no further information is provided regarding
how or who was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “...A total of 36 patients were enrolled but six of
these failed to attend for physiotherapy and two more
refused further injection when they came to cross over...
”
Comment: no information on handling of missing data
presented
Selective reporting (reporting bias) Unclear risk Comment: insufficient information to permit judgement
Other bias Unclear risk Comment: insufficient information to assess whether an
important risk of bias exists
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De Vos 2010
Methods Randomised controlled trial
Participants Setting: Sports medicine outpatient department, Netherlands
Sample: 54 participants, recruited through advertisements on websites, folders and re-
gional radio to health professionals and the public. Aged 18 to 70 years, all had clinically
diagnosed mid portion Achilles tendinopathy. Unilateral tendinopathy
Characteristics: 26 men and 28 women, mean (SD) 49 years (8.1) in the intervention
group and 50 years (9.4) in the control group
Interventions All patients received 2 ml of 0.5% bupivacaine hydrochloride in the skin and subcuta-
neous tissue. All injections were ultrasound-guided into several sites in the degenerative
area of the main body of the tendon. After 1 week all patients completed an additional
12-week eccentric loading programme. After 4 weeks all patients could return to full
sporting activities
Intervention: 54 ml of whole blood with 6 ml of citrate centrifuged for 15 minutes; 4
ml PRP layer extracted and added to 0.3 ml of 8.4% sodium bicarbonate buffer
Control: 4 ml isotonic saline
Outcomes All patients followed up at 6, 12 and 24 weeks
Primary: VISA-A
Secondary: patient satisfaction (poor, fair, good, excellent), return to sports, ultrasono-
graphic structure and adherence to the eccentric exercises
Notes 1-year follow-up data available in follow-up studies published by de Jonge 2011 and de
Vos 2011
The study was funded by Biomet Biologics LLC
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...patientswere randomised into 1of 2 treatment
groups by choosing a closed envelope. To ensure balance
in the number of patiens between the groups, a block
randomisation was performed...”
Comment: the investigators describe a random compo-
nent in the sequence generation process
Allocation concealment (selection bias) Low risk Quote: “...randomisation was performed using sealed
opaque, identical envelopes...”
Comment: the investigators’ assignment envelopes were
used with safeguards
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “...One unblinded sports medicine physician se-
lected the correct injection and blinded the injectionwith
the use of a covering sheath surrounding the syringe and
hub of the needle. To ensure concealment of allocation,
data on allocation were stored in a secret location. The
content on the injection was blinded for the treating
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De Vos 2010 (Continued)
sports medicine physician, research and patients...”
Comment: blinding of patients and personnel ensured
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: outcomes were patient-reported; all patients
were blinded to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “...There were no patients lost to follow up and
there were no missing data...”
Comment: no missing outcome data
Selective reporting (reporting bias) Low risk Comment: the study protocol is available and all of the
study’s pre-specified (primary and secondary) outcomes
have been reported in the pre-specified way
Other bias High risk Comment: the study was funded by Biomet Biologics
LLC
Fabbro 2012
Methods Randomised controlled trial
Participants Setting: not stated
Sample: 54 patients referred for ultrasound-guided treatment of mid portion Achilles
tendinopathy
Characteristics: 18 participants (11 males, mean (SD) 50.7 years (10.0)) in the steroid
injection group, 18 (9 males, mean (SD) 47.2 years (11.8)) in the dry needling only
group, and 18 participants (9 males, mean (SD) 45.7 years (8.6)) in the dry needling
and steroid injection group
Interventions Intervention 1: Steroid injection comprising ultrasound-guided injection of 1ml 40 mg/
ml triamcinolone acetonide into the peritendinous soft tissues, deliberately avoiding the
tendon substance
Control: dry needling comprising ultrasound-guided injection of local anaesthetic (5
ml 2% lidocaine) into the peritendinous soft tissues and tendon body. Dry needling
(around 20 punctures) was performed on the degenerated portion of the tendon. Post-
intervention use of appropriate orthotics for 1 week
Intervention 2: dry needling (as in control group) followed by peritendinous steroid
injection
Outcomes Follow-up was at days 7, 14, 30, 90, 180 and 360
The sole outcome measure was use of a visual analogue scoring system although it is not
stated what this explicitly refers to (pain on activity, disability, satisfaction, etc.)
Notes Data analysis: SD imputed for pain scores from other trials in the same analysis category
Risk of bias
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Fabbro 2012 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: no description of the randomisation process.
The only mention of randomisation is in the manuscript
title, which describes the study as a “randomised con-
trolled trial”
Allocation concealment (selection bias) Unclear risk Comment: no description of the randomisation process.
The only mention of randomisation is in the manuscript
title, which describes the study as a “randomised con-
trolled trial”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: investigators do not report blinding proce-
dures but blinding of care providers is unlikely given the
interventions under comparison
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: no statement about blinding of participants
or personnel
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: it is impossible to determine from the report
whether or not patients were lost to follow-up
Selective reporting (reporting bias) Unclear risk The protocol was not published beforehand and so it
is impossible to determine whether it was changed after
recruitment commenced
Other bias Unclear risk The trial is poorly reported and only described in outline.
It has not been possible to exclude other types of bias
from this report
Fredberg 2004
Methods Randomised controlled trial
Participants Setting: single hospital rheumatology and sports medicine service, Denmark
Sample: 24 amateur or professional athletes referred for surgery because of symptomatic
unilateral Achilles tendinopathy. Unilateral tendinopathy
Characteristics: 15 men and 9 women, mean (range) 43.7 years (24 to 55)
Interventions Intervention: 3.5 ml 10 mg/ml lidocaine and 0.5 ml Kenalog (containing 20 mg triam-
cinolone, a corticosteroid) was injected peri-tendinously under ultrasound guidance on
both sides of the thickest point of the tendon. Injections were administered at days 0, 7
and 21. The third injection was not given to patients who were asymptomatic following
2 injections. 4 days of rest was advised following each injection, after which patients
could return to normal activities limited only by pain
Control: 3.5 ml 1% lidocaine and 0.5 ml 20% intralipid (intralipid was added in order
to make the placebo look like the milky Kenalog solution). The injection schedule was
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Fredberg 2004 (Continued)
as per the intervention group
Outcomes Participants were followed up at days 0, 7, 21, 28, 6 months, and by telephone at 2 years
Outcome measures included tendon diameter as measured by ultrasound, pressure-pain
detection threshold as measured by pressure algometry, walking pain as reported on a
0 to 10 numerical rating scale, and reported side effects. No primary outcome measure
was identified
Notes The study combined patients with Achilles and patellar tendinopathy but has been
included as the populations were analysed and reported separately
Data analysis: SD imputed for pain scores from other trials in the same analysis category
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The athletes were randomised in four blocks of
six athletes”
Comment: no further details are given as to how the
randomised blocks were achieved
Allocation concealment (selection bias) Unclear risk Comment: no information pertaining to allocation con-
cealment is provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “It was not possible to tell the difference between
placebo and active treatment by colour or viscosity. All
the injections were administered by the same investigator
under blind conditions”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “One person was responsible for the randomisa-
tion and preparation of the injected medicine, however,
the same person had nothing to do with diagnostic pro-
cedures or monitoring of effects”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: follow-up data provided for all cases up until
2 years
Selective reporting (reporting bias) Unclear risk Comment: the trial protocol was not registered before-
hand and so it is not possible to identify any changes to
the protocol that occurred during or after the trial
Other bias High risk Comment: there was 100% cross-over of patients from
the placebo to the intervention groups at 6 months fol-
low-up due to lack of symptomatic improvement
Quote: “In both placebo groups... treatment regimenwas
discontinued because the athletes did not feel sufficient
improvement in all cases except one... In this way, all 24
athletes who were primarily treated with placebo were
subsequently administered steroid treatment.”
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Kearney 2013
Methods Pilot randomised controlled trial
Participants Setting: single outpatient orthopaedic department, UK
Sample: 20 patients with a clinical diagnosis of mid-substance Achilles tendinopathy.
Bilateral tendinopathy included (number not stated)
Characteristics: 7 men and 13 women, mean (range) 48.9 years (35 to 66)
Interventions Intervention: 52 ml venous blood was drawn, combined with anticoagulant citrate, then
centrifuged. The platelet layer was then extracted and injected into the Achilles tendon.
Patients were advised to return to normal activities as pain allowed
Control: eccentric loading programme involving 2 exercises: (1) Patient in a standing
position with the heel over the edge of a step and legs straight. The heels are then
lowered beyond the level of the step. (2) Same exercises with the knee slightly flexed to
maximise use of soleus. Both exercises were performed twice daily for 12 weeks before
being progressed from double-leg to single-leg then with added weight. A single session
included 3 sets of 15 repetitions of each exercise
Outcomes Follow-up at 6 weeks, 3 months and 6 months
Primary: VISA-A questionnaire
Secondary: EuroQol 5-Dimension questionnaire (EQ-5D)
Notes Bilateral cases randomised as 1 unit
Chartered Society Research Foundation provided funding for this pilot study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Treatment allocation was determined us-
ing a computer-generated randomnumber sequence
and administered by an independent trial co-ordi-
nator”
Allocation concealment (selection bias) Low risk Quote: “Treatment allocation was determined us-
ing a computer-generated randomnumber sequence
and administered by an independent trial co-ordi-
nator”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “It was not possible to blind the clinician ad-
ministering the intervention or the patient receiving
the intervention”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “The primary datawas patient-reported” and
“It was not possible to blind... the patient receiving
the intervention”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “One [patient] was lost to follow-up”
37Injection therapies for Achilles tendinopathy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Selective reporting (reporting bias) Low risk Quote: “The trial was registered on the current con-
trolled trials database ISRCTN95369715”before re-
cruitment commenced
Comment: the final trial protocol did not differ sub-
stantially from that published in advance
Other bias Low risk Quote: “Chartered Society Research Foundation
provided funding for this pilot study. They did not
have a role in study design, collection, analysis/in-
terpretation of data, writing of the manuscript or in
the decision to submit the manuscript for publica-
tion”
Larsen 1987
Methods Randomised controlled trial
Participants Setting: medical centre for Royal Life Guards, Denmark
Sample: 20 participants with clinical findings of tendinopathy. Bilateral tendinopathy
included (no data on whether this occurred)
Characteristics: all male. Mean age 20 years (SD 1 year)
Interventions All participants were advised to rest
Intervention: 5 injections of heparin (5000 IU)
Control: 5 isotonic saline injections (5000 IU)
Outcomes All outcomes were collected at day 5, 8 and 15
The main outcome measure was an investigator derived “total symptom score”
Pain (0 to 10 VAS) on resting and during exercise
Return to military training
Adverse events
Notes Bilateral tendinopathy randomised as one unit
Data analysis: SD imputed for pain scores from other trials in the same analysis category
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomised packages of heparin and of the
placebo were provided by Leo Pharmaceuticals”
Comment: insufficient information provided
Allocation concealment (selection bias) Unclear risk Comment: no description provided by the authors
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: no description provided by the authors
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Larsen 1987 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: no description provided by the authors
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: incomplete data and methods for handling
not described
Selective reporting (reporting bias) Unclear risk Comment: the trial protocol was not registered before-
hand and so it is not possible identify any changes to the
protocol that occurred during or after the trial
Other bias High risk Quote: “..Leo Pharmaceutical Products are thanked for
their assistance”
Comment: the trial is poorly reported and only described
in outline. It has not been possible to exclude other types
of bias from this report
Obaid 2012
Methods Randomised controlled trial
Participants Setting: single specialist orthopaedic hospital, UK
Sample: 32 participants with a clinical and sonographic diagnosis of non-insertional
Achilles tendinosis. Bilateral tendinopathy included
Characteristics: 32 participants (20 male, 12 female), 8 of which had bilateral Achilles
tendinopathy, mean (range) 45.2 years (22 to 67)
Interventions Intervention: injection of 5ml 0.25%bupivacaine hydrochloride onto the ventral surface
of the Achilles tendon at its midsection with subsequent re-positioning of the needle
and injection with a combination of skin-derived fibroblasts and autologous platelet-rich
plasma. Participants were advised to rest for 48 hours before commencing a programme
of eccentric-loading physiotherapy
Control: injection of 5 ml 0.25% bupivacaine hydrochloride onto the ventral surface of
the Achilles tendon at its midsection. Advice and physiotherapy were administered as in
the intervention group
Outcomes Follow-up was at 6 weeks after physiotherapy, at the time of harvesting fibroblasts from
skin, at cell implantation and at 6 weeks, 3 months and 6 months post intervention
Outcomes included score on the VISA-A questionnaire, patient-reported level of health
using a VAS score, and ultrasound assessment
Notes Bilateral tendinopathy randomised per tendon
The study was funded by an Austrian biotechnology company, Innovacell
Risk of bias
Bias Authors’ judgement Support for judgement
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Obaid 2012 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “The patients were randomised with use of a se-
quence of random numbers from a computer-generated
sequence”
Allocation concealment (selection bias) Unclear risk Comment: no explicit statement that allocation to groups
was concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: no explicit statement that participants and
personnel were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Blinding was carried out at all evaluations”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all included cases followed up according to
the study flow diagram
Selective reporting (reporting bias) Unclear risk Comment: the protocol was not published beforehand
and so it is impossible to determine whether it was
changed after recruitment commenced
Other bias High risk Comment: the study was funded by an Austrian biotech
company, Innovacell. There was no explicit statement as
to the involvement of this company in the study design,
data collection, analysis or decision to publish
Pearson 2012
Methods Randomised controlled trial
Participants Setting: private sports medicine clinic, New Zealand
Sample: 33 participants with 40 clinical and sonographic diagnosis of Achilles tendinopa-
thy. Bilateral tendinopathy included
Characteristics: treatment group: 8 male and 12 female, age 49 years (range 34 to 65);
control group: 7 male and 13 female, age 51 years (range 42 to 70)
Interventions Intervention: 1 ml lignocaine 1% at the point of maximal tenderness and 3 ml of
autologous blood, followed by an eccentric loading programme within 48 hours
Control: eccentric loading programme
Outcomes Follow-up was at 6 and 12 weeks
Primary: VISA-A
Secondary: perceived discomfort on a Likert scale
Notes Patients with bilateral tendinopathy were randomised per tendon
Pacific radiology performed the ultrasounds free of charge to the patients
Data analysis: SD imputed for VISA-A scores from other trials in the same analysis
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Pearson 2012 (Continued)
category
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: no description provided
Allocation concealment (selection bias) High risk Quote: “Bilateral tendinopathy cases were randomly al-
located with one tendon to the treatment group and one
to the control group”
Comment: participants and investigators could foresee
assignments in these cases
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “No placebo injection was performed; hence nei-
ther patients nor treatment providers were blind to the
treatment allocation”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: the study did not address this outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: missing data balanced in numbers across in-
tervention groups, with similar reasons for missing data
across groups
Selective reporting (reporting bias) Unclear risk Comment: the protocol was not published beforehand
and so it is impossible to determine whether it was
changed after recruitment commenced
Other bias Unclear risk Quote: “Pacific Radiology performed the ultrasounds
free of charge to the patients”
Pforringer 1994
Methods Randomised controlled trial
Participants Setting: single orthopaedic clinic in Munich, Germany
Sample: 60 recreational and professional athletes with a clinical diagnosis of Achilles ten-
don pain and thickening of the tendon on ultrasound examination.Unilateral tendinopa-
thy only
Characteristics: mean (SD) 31.0 years (7.5) in the treatment and 34.0 (10.4) in the
placebo arm
Interventions Intervention: paratendinous injection with 5 ml 1% local anaesthetic (mepivacaine hy-
drochloride) with 5 ml of the study preparation (haemodialysate). Further injections
were administered after 3 to 4 days and 9 to 10 days. All patients were also given a soft
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Pforringer 1994 (Continued)
pad heel support
Control: as in the intervention group, although the study preparation was substituted
for 5 ml 0.9% saline solution
Outcomes Follow-up was 3 time points; at 3 to 4, 9 to 10 and 20 to 23 days
Primary: tendon diameter and density as determined by ultrasound
Secondary: patient-reported pain on walking, running and full activity (“no symptoms”,
“mild symptoms”, “severe symptoms”), pain whilst standing on tiptoes, squatting and on
palpation (“no pain”, “mild pain”, “moderate pain”, “severe pain”) and overall patient-
reported pain on a 0 to 10 scale
Notes Data analysis: SD imputed for pain scores from other trials in the same analysis category
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: unclear description
Quote: “The patients were allocated to the treatment
groups according to a randomization list, which theman-
ufacture of the coded medications was based”
Allocation concealment (selection bias) Unclear risk Comment: no clear statement as towhether the allocation
was concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: the placebo solution had “identical appear-
ance to the drug”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although described in the manuscript as a
“double-blind” trial, there was no explicit statement that
the assessors were blinded to the study group
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: it is not possible to determine from the report
whether any patients were lost to follow-up
Selective reporting (reporting bias) Unclear risk Comment: the protocol was not published beforehand
and so it is impossible to determine whether it was
changed after recruitment commenced
Other bias Unclear risk Comment: no statement as to sources of study funding
or conflicts of interest
42Injection therapies for Achilles tendinopathy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sundqvist 1987
Methods Randomised controlled trial
Participants Setting: department of orthopaedic surgery, Sweden
Sample: 60 recreational/competitive athletes with clinically diagnosed tendinopathy.
Unilateral tendinopathy only
Characteristics: 51 males and 8 females (1 participant excluded with no additional data)
. Mean age 33 years (range 21 to 52)
Interventions All were prescribed a period of restricted training for at least 14 days and provided with
a stretching programme and orthotics as required
Intervention: 6 local injections of glycosaminoglycan polysulphate (50 mg/ml, 3 injec-
tions a week) combined with 3 x 1 placebo tablets
Control: 6 placebo injections (1 ml saline) combined with 3 x 50 mg high-dose in-
domethacin
Outcomes All were assessed at week 2, week 4, month 6 and month 12
Outcomes included symptoms, pain on palpation, physicians’ evaluation of therapeutic
effect and the patients’ opinions on howmuch the injury impeded his/her sports training
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “By using random number code the patiens were
allocated to one of two treatment groups”
Comment: the investigators describe a random compo-
nent in the sequence generation process
Allocation concealment (selection bias) Unclear risk Comment: insufficient information presented to permit
judgement of low or high risk
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: insufficient information presented on blind-
ing procedures
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: insufficient information presented on blind-
ing procedures
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: missing data not reported
Selective reporting (reporting bias) Unclear risk Comment: the protocol was not published beforehand
and so it is impossible to determine whether it was
changed after recruitment commenced
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Sundqvist 1987 (Continued)
Other bias Unclear risk Comment: the trial is poorly reported and only described
in outline. It has not been possible to exclude other types
of bias from this report
Willberg 2008
Methods Randomised controlled trial
Participants Setting: a single sports medicine clinic in Stockholm, Sweden
Sample: 48 patients with 52 symptomatic mid portion tendinopathy referred to a single
clinic by primary care practitioners
Characteristics: mean (SD) 51.8 years (12.4) in the 10 mg/ml group and 47.4 years (7.
8) in the 5 mg/ml group. Male/female ratio (by tendon) was 20/6 in the 10 mg/ml group
and 15/11 in the 5 mg/ml group. Bilateral tendinopathy included (4 participants)
Interventions Intervention (high-dose): ultrasound-guided injection of small volumes of polidocanol
10 mg/ml into areas of local neovascularisation outside the tendon. Full Achilles tendon
loadingwas permitted 14days after each treatment. 3 treatments (at 6 to 8-week intervals)
were given before the first evaluation, after which participants with persisting symptoms
were offered further injections
Intervention (low-dose): as in the high-dose intervention but using polidocanol 5 mg/
ml. Participants with persisting symptoms were offered further injections but of 10 mg/
ml after the third treatment
Outcomes Follow-up time points not specified; mean follow-up 14 months (range 2 to 35 months)
Outcome measures included pain on activity scored on a visual analogue scale, self
reported patient satisfaction, number of treatments needed to restore patients to the pre-
injury Achilles tendon loading activities, total volume of polidocanol injections before
achieving this result, and adverse events
Notes Funding for the study has been achieved through the Swedish Research Council for
Sports
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The patients selected an envelope (52 opaque
envelopes), allocating themselves to either treatmentwith
Polidocanol 5 or 10mg/ml”
Allocation concealment (selection bias) Low risk Quote: “The patients selected an envelope (52 opaque
envelopes), allocating themselves to either treatmentwith
Polidocanol 5 or 10mg/ml”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The chosen envelope was opened in a separate
room by an assistant and the substance was prepared by
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Willberg 2008 (Continued)
the assistant for injection. There were no visible differ-
ences (colour, density, etc) between the substances”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The patients, the treating orthopaedic sur-
geon, the sonographer, who performed all ultrasound
and colour Doppler examinations and treatments were
blinded to the substance that was injected”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “Participants left the study at the point at which
they became asymptomatic.”
Comment: departure from the study was therefore col-
lected as an outcomemeasure. There were no participants
remaining in either group after the fifth treatment
Selective reporting (reporting bias) Unclear risk Comment: the trial protocol was not registered before-
hand and so it is not possible identify any changes to the
protocol that occurred during or after the trial
Other bias Unclear risk Quote: “Funding for the study has been achieved through
the Swedish Research Council for Sports”. There was no
explicit statement as to the involvement of this funding
body
Yelland 2011
Methods Randomised controlled trial
Participants Setting: 5 Australian primary care centres
Sample: 43 patients aged > 18 with mid-portion Achilles tendinosis. The participants
were recruited from clinician referrals and advertising in newspapers, brochures and
online
Characteristics: mean age (range) 46 years (40 to 58) in the eccentric loading exercises
group, 48 years (41 to 54) in the prolotherapy group, and 46 years (40 to 57) in the
combined treatment group. Bilateral tendinopathy included (15 participants). No in-
formation on gender distribution
Interventions Intervention: injection of tender points in the subcutaneous tissues adjacent to the
affected tendon with 20% glucose, 0.1% lignocaine and 0.1% ropivacaine weekly for 4
to 12 weeks. Treatment ceased when the patient reported pain-free activity or requested
to stop receiving injections
Control: standardised eccentric loading exercises (3 sets of 15 repetitions each with the
knee straight then flexed) twice daily for 12 weeks
Combined interventions: protocols for injection and eccentric loading exercise groups
implemented concurrently
Outcomes Follow-up was at 6 weeks and month 3, 6 and 12
Primary: VISA-A questionnaire by telephone at 6 weeks, 3 months, 6 months and 12
months. The criterion for treatment success was set a priori as an increase in 20 points
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Yelland 2011 (Continued)
on the VISA-A score
Secondary: 7-point Likert scale for treatment satisfaction, the Patient Global Impression
of Change scale, and 0 to 10 scales for worst pain in the last week, usual morning stiffness
and limitation of normal activities
Notes Bilateral tendinopathy randomised per unit
The trial was funded by grants from the Musculoskeletal Research Foundation of Aus-
tralia, the Australian Podiatry Education and Research Foundation and the Griffith Uni-
versity Office of Research
Data analysis: SD imputed for VISA-A scores from other trials in the same analysis
category
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomisation schedule was generated and
administered by telephone independently by the Na-
tionalHealth andMedical ResearchCouncil Clinical Tri-
als Centre in Sydney, Australia”
Allocation concealment (selection bias) Low risk Quote: “The randomisation schedule was generated and
administered by telephone independently by the Na-
tionalHealth andMedical ResearchCouncil Clinical Tri-
als Centre in Sydney, Australia”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: no explicit statement, however participants
must have known whether theywere receiving an exercise
regimen, injections or both
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: no statement as to whether the assessors were
blinded as to the study group. The primary outcome
measure was patient-reported and the patient could not
have been blinded as to the arm to which they were ran-
domised
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “The proportion of missing final outcome mea-
surements is small (<3% for the primary outcome mea-
sure), and they are imputed by carrying the last value
forward method”
Selective reporting (reporting bias) Unclear risk Comment: the protocol was not published beforehand
and so it is impossible to determine whether it was
changed after recruitment commenced
Other bias Low risk Quote: “The trial was funded by grants from the Mus-
culoskeletal Research Foundation of Australia, the Aus-
tralian Podiatry Education and Research Foundation and
the Griffith University Office of Research. The funding
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Yelland 2011 (Continued)
bodies had no role in the study design; in the collection,
analysis and interpretation of data; in the writing of the
report or in the decision to submit the paper for publi-
cation”
PRP = platelet-rich plasma
SD = standard deviation
VAS = visual analogue scale
VISA-A = Victorian Institute of Sport Assessment-Achilles questionnaire
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ferrero 2012 Prospective cohort study without any attempt to randomise patients or compare injection therapies with a control
intervention
Characteristics of studies awaiting assessment [ordered by study ID]
EUCTR2010-020513-87
Methods Randomised, placebo-controlled, double-blind trial
Participants Inclusion criteria:
Aged 18 to 70 years
• Diagnosis of chronic (symptoms persisting for over 6 weeks) or subacute (symptoms persisting for
approximately 3 to 6 weeks) tendinitis of the Achilles tendon, diagnosed clinically and/or by means of ultrasound
• Pain in the Achilles tendon at rest or after moderate physical activity
• Presence of at least 1 of the following parameters: swelling of the tendon, increase in local temperature (to the
touch), pain upon touching or applying pressure, limited range of joint motion
• Total score on VISA-A less than 60
• Non-responder to traditional tendinitis therapy: anti-inflammatory and/or physical therapy
• Non-responder to abstinence from the physical activity causing pain to the Achilles tendon
Exclusion criteria:
• Tendinitis in acute inflammatory phase
• Lateral instability of the ankle
• Obesity: BMI > 35 kg/m2
• Bilateral tendinitis
• History of diabetes mellitus or any other disease which in the investigator’s opinion might influence the
experimental data
• Presence of areas of degeneration in the tendon (tendinosis)
• History of arthritic and/or metabolic disease
• Suspected (based on clinical judgement or tests) structural lesions of the tendon (previous or current)
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EUCTR2010-020513-87 (Continued)
• Previous major trauma to the Achilles tendon
• Previous surgery on the Achilles tendon under evaluation or on the same ankle
• Oral, parenteral or intra-articular use of corticosteroids during the 3 months previous to enrolment in the study
• Infiltration therapy with hyaluronic acid on the Achilles tendon under evaluation during the 3 months
previous to enrolment in the study
• Para-tendinopathy
• Pregnancy
• Participation in other clinical trials during the 3 months previous to enrolment in the study
Interventions Intervention was injection with hyaluronic acid. Control arm not described
Outcomes Primary outcome measure using the VISA-A questionnaire. Secondary outcome measures include:
• Efficacy of the therapy in improving the clinical profile of the disease
• Efficacy of the therapy in improving ultrasound results (thickness of tendon, presence of oedema, of tendinosis
and signs of phlogosis)
• Efficacy of the therapy in terms of patient satisfaction and medical judgement
• Anti-inflammatory drugs consumption
• Local and systemic tolerance of the therapy
Notes https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract˙number:2010-020513-87. Reported
completed but not published
Petrella 2013
Methods Randomised placebo-controlled trial (use of computerised random number generator)
Participants 35 participants with a chronic recalcitrant (> 6 months) non-insertional Achilles tendinopathy
Interventions Hyaluronan (2.8 cc, 730 to 1300 kDa) or normal saline (2.8 cc) was injected peri-tendinously under ultrasound
guidance at baseline and 7 days
Outcomes Follow-up: days 7, 14, 30 and 90
Primary outcome measure: VISA-A (Victorian Institute of Sport Assessment - Achilles) score
Secondary outcomes: pain VAS on weight bearing (0 to 100 mm), patients’ global assessment of Achilles injury
(5-point categorical scale), patients’ assessment of normal function/activity (5-point categorical scale), physician’s
global assessment of Achilles injury (5-point categorical scale), patients/physician satisfaction assessment (10-point
categorical scale), time to return to pain-free and disability-free sport and adverse events as per WHO definition
Notes Reported in abstract form only
BMI = body mass index
VAS = visual analogue scale
VISA-A = Victorian Institute of Sport Assessment - Achilles scale
WHO = World Health Organization
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Characteristics of ongoing studies [ordered by study ID]
ISRCTN85334402
Trial name or title A trial evaluating the efficacy of cell therapy based on autologous platelet rich plasma (PRP) for the treatment
of Achilles and patellar tendinopathies
Methods Double-blind randomised controlled trial
Participants 128 patients (64 with Achilles and 64 with patellar tendinopathy)
Interventions Intervention was ultrasound-guided injection of platelet-rich plasma. The control group will receive an
ultrasound-guided injection of platelet-poor plasma
Outcomes Victorian Institute of Sport Assessment Questionnaire (VISA)-A for Achilles tendinopathy and -P for patellar
tendinopathy. Foot and Ankle Ability Measure. Visual analogue scale (VAS) 0 to 10. Participant-reported
overall satisfaction and response to treatment at 4 weeks, 2 months, 4 months and 12 months
Starting date 8 October 2013
Contact information Dr Ilias Petrou, Regenerative TherapyUnit (UTR), Service of Plastic and Reconstructive Surgery,Department
of Musculoskeletal Medicine DAL, CHUV-EPCR/Croisettes 22, Epalinges, Switzerland
Notes -
NCT01343836
Trial name or title Autologous tenocyte implantation in patients with chronic Achilles tendinopathy (ATI)
Methods Double-blind randomised controlled trial
Participants Participants aged 18 to 55 years with symptoms of > 2 months duration that include pain on palpation 2 to
7 cm proximal from the tendon insertion. Exclusion criteria are:
• clinical suspicion of insertional disorders, Achilles tendon rupture, plantar flexor tenosynovitis, sural
nerve pathology, peroneal subluxation;
• condition of the Achilles tendon caused by medications such as quinolones and statins;
• known to have the following disorders: spondyloarthropathy, gout, hyperlipidaemia, rheumatoid
arthritis and sarcoidosis;
• antibiotics allergy (aminoglycoside group);
• a condition that prevents the patients from executing an active rehabilitation programme;
• patient has received an injection for this injury;
• patient has received surgical intervention for this injury;
• patient has already one site (left or right) included in this study;
• patient does not wish, for whatever reason, to undergo one of the 2 treatments;
• known pregnancy;
• nursing women.
Interventions Interventionwas ultrasound-guided intratendinous autologous tenocyte implantationwith eccentric exercises.
The control arm received ultrasound-guided intratendinous saline injection with eccentric exercises
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NCT01343836 (Continued)
Outcomes Primary outcome measure VISA-A score at 24 weeks post-intervention
Secondary outcome measures are ultrasonographic tendon repair
Starting date April 2011
Contact information Dr S. de Jonge, Sports Medicine Department Medical Center, The Hague Leidschendam, Zuid-Holland,
Netherlands, 2262 BA
Notes -
NCT01583504
Trial name or title A double blind, randomised controlled trial of high volume saline injections for chronic midportion Achilles
tendinopathy
Methods Randomised, double-blind, controlled trial
Participants Participants aged 18+withmore than 13weeks of pain in the Achilles tendon area, completed eccentric tendon
loading programme with a physiotherapist, Achilles tendon tender to palpation in the midportion, tendon
diameter greater than 0.7 cm on ultrasound scan, evidence of neovascularisation on doppler ultrasound scan,
sufficient English language to complete questionnaires and consent. Exclusion criteria are ultrasound evidence
or previous history of partial or full tendon tear, another co-existing significant foot or ankle pathology,
taking anticoagulant medication, i.e. warfarin, clopidogrel, dipyridamole, a medical condition that would
affect safety of injection, i.e. diabetic neuropathy, peripheral vascular disease, previous Achilles tendon surgery,
unable to give informed consent
Interventions Intervention group is ultrasound-guided injectionof steroid, local anaesthetic andhigh-volume saline.Control
arm received ultrasound-guided injection of steroid and local anaesthetic only
Outcomes Primary outcome measure 100 mm visual analogue scale (VAS) at 6 weeks post-injection
Secondary outcome measures include Foot and Ankle Outcome Score, EQ5D-3L, ultrasound measurement
of Achilles tendon diameter, neovascularisation grading at 6, 12 and 40 weeks
Starting date March 2012
Contact information Ms Marie Hoddell, Leeds Musculoskeletal and Rehabilitation Service, Leeds, West Yorkshire, LS7 4SA
Notes -
NCT01954108
Trial name or title Hyaluronan in the treatment of painful Achilles tendinopathy
Methods Randomised, single-blind trial
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Participants Participants aged 18 to 75. Inclusion criteria:
• Male and female patients between 18 and 75 years of age
• Good general health condition
• Signed written informed consent
• Painful Achilles midportion tendinopathy for more than or equal to 6 weeks
• Pain according to VAS (Huskisson, 100 mm) more than or equal to 40 mm
• Ensured compliance of participants over the whole study period
Exclusion criteria:
• Concomitant or previous participation in a clinical investigation within the last 3 months prior to
study inclusion
• Infection or relevant skin disease at study relevant site
• Blood coagulation disorder or intake of blood thinner (e.g. Marcumar)
• Known hypersensitivity to hyaluronic acid (HA) preparations or to the constituents mannitol, sodium
chloride, disodium phosphate and sodium dihydrogenphosphate
• Contra-indications for ESWT application in study relevant area (e.g. recent surgery, malignant
tumour, local osteomyelitis or open epiphysis)
• Severe intercurrent illness (e.g. uncontrolled diabetes mellitus, peripheral neuropathy), which in the
opinion of the investigator, may put the patient at risk when participating in the study, or affect the patient’s
ability to take part in the study
• Concomitant disease at study relevant site (e.g. insertion tendinopathy at Achilles tendon) influencing
study evaluation
• Diseases or characteristics judged by the investigator to be incompatible with the assessments and/or
procedures for the study evaluation
• Intake of concomitant medications not allowed which might interfere with the functional assessment
of the study (e.g. immunosuppressive drugs within the last 3 months)
• Previous therapies (except non-steroidal anti-inflammatory drugs (NSAIDs)) at study relevant site
within the last 4 weeks prior to study inclusion
• Use of NSAIDs within the last week prior to study treatment
• Recent history of drug and/or alcohol abuse (within the last 6 months)
• Pregnant or lactating females
• Participants of childbearing age (pre-menopausal) who do not accept the use of methods of birth
control with pearl index of at least 1 (i.e. oral contraceptives, vaginal ring, hormone-releasing intrauterine
device (IUD), implants, depot syringes, hormone patch, double barrier method, tubal ligation,
vasectomised partner…) during the treatment period and the first 4 weeks of follow-up period
• Participants not capable of contracting and of understanding the nature, risks, significance and
implications of the clinical investigation and unable to form a rational intention in the light of these facts
• Participants unable to understand informed consent or having a high probability of non-compliance
with the study procedures and/or non-completion of the study according to investigator’s judgement (e.g.
illiteracy, insufficient knowledge of local language)
Interventions Intervention group was extracorporeal shock wave therapy versus a second arm that received hyaluronic acid
injections
Outcomes VISA-A scores at regular intervals post-intervention, clinical parameters (redness, warmth, swelling, tender-
ness, crepitus, fluid accumulation) on a 5-point scale at days 7, 28, 90 and 180, and adverse events
Starting date December 2013
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Contact information Dr Petra Dobner, dobner@trbchemedica.de
Notes Estimated completion date April 2015
ESWT = extracorporeal shock wave therapy
VAS = visual analogue scale
VISA-A = Victorian Institute of Sport Assessment - Achilles scale
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D A T A A N D A N A L Y S E S
Comparison 1. Injection therapies versus placebo injection or no injection control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 VISA-A (score 0 to 100; 100 =
no problems): at 6 weeks
5 200 Mean Difference (IV, Fixed, 95% CI) 0.79 [-4.56, 6.14]
1.1 Injury-causing agents 1 28 Mean Difference (IV, Fixed, 95% CI) 4.0 [-12.30, 20.30]
1.2 Direct repair agents 4 172 Mean Difference (IV, Fixed, 95% CI) 0.40 [-5.26, 6.06]
2 VISA-A (score 0 to 100; 100 =
no problems): at 3 months
5 189 Mean Difference (IV, Fixed, 95% CI) -0.94 [-6.34, 4.46]
2.1 Injury-causing agents 1 27 Mean Difference (IV, Fixed, 95% CI) -5.0 [-21.61, 11.61]
2.2 Direct repair agents 4 162 Mean Difference (IV, Fixed, 95% CI) -0.46 [-6.17, 5.25]
3 VISA-A (score 0 to 100; 100 =
no problems): after 3 months
3 132 Mean Difference (IV, Fixed, 95% CI) 0.14 [-6.54, 6.82]
3.1 Injury-causing agents 1 27 Mean Difference (IV, Fixed, 95% CI) 9.5 [-6.35, 25.35]
3.2 Direct repair agents 2 105 Mean Difference (IV, Fixed, 95% CI) -1.88 [-9.25, 5.48]
4 Patients achieving increased
VISA-A scores (20 points or
more from baseline)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Injury-causing agent vs
exercises: 6 weeks
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Injury-causing agent vs
exercises: 3 months
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Injury-causing agent vs
exercises: 12 months
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Adverse events 13 449 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.50, 1.89]
5.1 Injury-causing agents 2 47 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.01, 7.02]
5.2 Direct repair agents 11 402 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.53, 2.09]
6 Pain (VAS; score 0 to 100; 0 =
no pain) up to 3 months
7 219 Mean Difference (IV, Random, 95% CI) -22.94 [-37.53, -8.
36]
6.1 Injury-causing agents 2 47 Mean Difference (IV, Random, 95% CI) -12.31 [-30.43, 5.
81]
6.2 Direct repair agents 5 172 Mean Difference (IV, Random, 95% CI) -26.34 [-44.13, -8.
55]
7 Return to sports 7 335 Risk Ratio (M-H, Random, 95% CI) 1.39 [1.00, 1.94]
7.1 Injury-causing agents 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Direct repair agents 7 335 Risk Ratio (M-H, Random, 95% CI) 1.39 [1.00, 1.94]
8 Patient satisfaction with
treatment (an event represents
satisfaction with treatment)
4 152 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.76, 1.47]
8.1 Injury-causing agents 2 47 Risk Ratio (M-H, Random, 95% CI) 2.79 [0.26, 29.91]
8.2 Direct repair agents 2 105 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.85, 1.14]
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Comparison 2. Injection therapies versus active treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 VISA-A (score 0 to 100; 100 =
no problems)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
1.1 Direct repair agent vs
exercises: at 6 weeks
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Direct repair agent vs
exercises: at 3 months
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 Direct repair agent vs
exercises: after 3 months (6
months)
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 Patients achieving increased
VISA-A scores (20 points or
more from baseline)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Injury-causing agent vs
exercises: 6 weeks
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Injury-causing agent vs
exercises: 3 months
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Injury-causing agent vs
exercises: 12 months
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Adverse events 3 66 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.04, 2.99]
3.1 Injury-causing agent vs
surgery
1 20 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.02, 7.32]
3.2 Injury-causing agent vs
eccentric exercises
1 26 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.50]
3.3 Direct repair agent vs
eccentric exercises
1 20 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Quality of life: EQ-5D (scores
up to 1: full health)
1 19 Mean Difference (IV, Fixed, 95% CI) 0.08 [-0.25, 0.41]
4.1 Direct repair agent vs
eccentric exercises
1 19 Mean Difference (IV, Fixed, 95% CI) 0.08 [-0.25, 0.41]
5 Patient satisfaction with
treatment (satisfied patients)
2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Injury-causing agent vs
surgery
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Injury-causing agent vs
eccentric exercises
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 3. High-dose versus low-dose injection therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Pain during activity (VAS; score
0 to 100; 0 = no pain) after
maximum of 3 treatments
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Patient satisfaction (satisfied
patients)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 After 3 treatments 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 After 5 treatments 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Injection therapies versus placebo injection or no injection control, Outcome 1
VISA-A (score 0 to 100; 100 = no problems): at 6 weeks.
Review: Injection therapies for Achilles tendinopathy
Comparison: 1 Injection therapies versus placebo injection or no injection control
Outcome: 1 VISA-A (score 0 to 100; 100 = no problems): at 6 weeks
Study or subgroup Injection therapy Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Injury-causing agents
Yelland 2011 (1) 14 74 (22) 14 70 (22) 10.8 % 4.00 [ -12.30, 20.30 ]
Subtotal (95% CI) 14 14 10.8 % 4.00 [ -12.30, 20.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
2 Direct repair agents
Bell 2013 26 66 (20) 26 63 (15) 31.0 % 3.00 [ -6.61, 12.61 ]
Brown 2006 (2) 14 71 (19) 16 71 (17) 17.0 % 0.0 [ -12.98, 12.98 ]
De Vos 2010 27 55 (17) 27 57 (18) 32.8 % -2.00 [ -11.34, 7.34 ]
Pearson 2012 (3) 18 62 (30) 18 61 (26) 8.5 % 1.00 [ -17.34, 19.34 ]
Subtotal (95% CI) 85 87 89.2 % 0.40 [ -5.26, 6.06 ]
Heterogeneity: Chi2 = 0.54, df = 3 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Total (95% CI) 99 101 100.0 % 0.79 [ -4.56, 6.14 ]
Heterogeneity: Chi2 = 0.71, df = 4 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Chi2 = 0.17, df = 1 (P = 0.68), I2 =0.0%
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(1) Injection therapy and exercise versus exercise; SD imputed from data of similar studies using the same outcome measure at same outcome point
(2) SD imputed from data of similar studies using the same outcome measure at same outcome point
(3) SD imputed from data of similar studies using the same outcome measure at same outcome point
Analysis 1.2. Comparison 1 Injection therapies versus placebo injection or no injection control, Outcome 2
VISA-A (score 0 to 100; 100 = no problems): at 3 months.
Review: Injection therapies for Achilles tendinopathy
Comparison: 1 Injection therapies versus placebo injection or no injection control
Outcome: 2 VISA-A (score 0 to 100; 100 = no problems): at 3 months
Study or subgroup Injection therapy Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Injury-causing agents
Yelland 2011 (1) 14 76 (22) 13 81 (22) 10.6 % -5.00 [ -21.61, 11.61 ]
Subtotal (95% CI) 14 13 10.6 % -5.00 [ -21.61, 11.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
2 Direct repair agents
Bell 2013 25 73 (17) 26 72 (15) 37.6 % 1.00 [ -7.81, 9.81 ]
Brown 2006 (2) 13 85 (18) 16 84 (15) 19.5 % 1.00 [ -11.24, 13.24 ]
De Vos 2010 27 56 (20) 27 63 (20) 25.6 % -7.00 [ -17.67, 3.67 ]
Pearson 2012 (3) 14 73 (29) 14 61 (27) 6.8 % 12.00 [ -8.76, 32.76 ]
Subtotal (95% CI) 79 83 89.4 % -0.46 [ -6.17, 5.25 ]
Heterogeneity: Chi2 = 2.99, df = 3 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
Total (95% CI) 93 96 100.0 % -0.94 [ -6.34, 4.46 ]
Heterogeneity: Chi2 = 3.24, df = 4 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Chi2 = 0.26, df = 1 (P = 0.61), I2 =0.0%
-20 -10 0 10 20
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(1) Injection therapy and exercise versus exercise; SD imputed from data of similar studies using the same outcome measure at same outcome point
(2) SD imputed from data of similar studies using the same outcome measure at same outcome point
(3) SD imputed from data of similar studies using the same outcome measure at same outcome point
Analysis 1.3. Comparison 1 Injection therapies versus placebo injection or no injection control, Outcome 3
VISA-A (score 0 to 100; 100 = no problems): after 3 months.
Review: Injection therapies for Achilles tendinopathy
Comparison: 1 Injection therapies versus placebo injection or no injection control
Outcome: 3 VISA-A (score 0 to 100; 100 = no problems): after 3 months
Study or subgroup Injection therapy Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Injury-causing agents
Yelland 2011 (1) 14 91.5 (21) 13 82 (21) 17.8 % 9.50 [ -6.35, 25.35 ]
Subtotal (95% CI) 14 13 17.8 % 9.50 [ -6.35, 25.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
2 Direct repair agents
Bell 2013 25 77 (17) 26 77 (17) 51.3 % 0.0 [ -9.33, 9.33 ]
De Vos 2010 27 68 (22) 27 73 (23) 31.0 % -5.00 [ -17.01, 7.01 ]
Subtotal (95% CI) 52 53 82.2 % -1.88 [ -9.25, 5.48 ]
Heterogeneity: Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
Total (95% CI) 66 66 100.0 % 0.14 [ -6.54, 6.82 ]
Heterogeneity: Chi2 = 2.04, df = 2 (P = 0.36); I2 =2%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Chi2 = 1.63, df = 1 (P = 0.20), I2 =39%
-50 -25 0 25 50
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(1) Injection therapy and exercise versus exercise; SD imputed from data of similar studies using the same outcome measure at same outcome point
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Analysis 1.4. Comparison 1 Injection therapies versus placebo injection or no injection control, Outcome 4
Patients achieving increased VISA-A scores (20 points or more from baseline).
Review: Injection therapies for Achilles tendinopathy
Comparison: 1 Injection therapies versus placebo injection or no injection control
Outcome: 4 Patients achieving increased VISA-A scores (20 points or more from baseline)
Study or subgroup Injection therapy Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Injury-causing agent vs exercises: 6 weeks
Yelland 2011 7/14 3/15 2.50 [ 0.80, 7.81 ]
2 Injury-causing agent vs exercises: 3 months
Yelland 2011 8/14 8/15 1.07 [ 0.56, 2.06 ]
3 Injury-causing agent vs exercises: 12 months
Yelland 2011 12/14 11/15 1.17 [ 0.81, 1.70 ]
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Analysis 1.5. Comparison 1 Injection therapies versus placebo injection or no injection control, Outcome 5
Adverse events.
Review: Injection therapies for Achilles tendinopathy
Comparison: 1 Injection therapies versus placebo injection or no injection control
Outcome: 5 Adverse events
Study or subgroup Injection therapy Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Injury-causing agents
Alfredson 2005 0/10 0/10 Not estimable
Yelland 2011 (1) 0/14 1/13 11.0 % 0.31 [ 0.01, 7.02 ]
Subtotal (95% CI) 24 23 11.0 % 0.31 [ 0.01, 7.02 ]
Total events: 0 (Injection therapy), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
2 Direct repair agents
Bell 2013 0/25 0/26 Not estimable
Brown 2006 (2) 3/13 9/13 63.8 % 0.33 [ 0.12, 0.96 ]
Capasso 1993 (3) 4/49 0/11 5.7 % 2.16 [ 0.12, 37.45 ]
Chouchane 1989 (4) 4/14 2/18 12.4 % 2.57 [ 0.55, 12.08 ]
DaCruz 1988 0/13 0/10 Not estimable
De Vos 2010 0/27 0/27 Not estimable
Fredberg 2004 (5) 1/12 0/12 3.5 % 3.00 [ 0.13, 67.06 ]
Larsen 1987 (6) 2/10 0/10 3.5 % 5.00 [ 0.27, 92.62 ]
Obaid 2012 0/12 0/12 Not estimable
Pearson 2012 0/14 0/14 Not estimable
Sundqvist 1987 0/30 0/30 Not estimable
Subtotal (95% CI) 219 183 89.0 % 1.05 [ 0.53, 2.09 ]
Total events: 14 (Injection therapy), 11 (Control)
Heterogeneity: Chi2 = 7.61, df = 4 (P = 0.11); I2 =47%
Test for overall effect: Z = 0.15 (P = 0.88)
Total (95% CI) 243 206 100.0 % 0.97 [ 0.50, 1.89 ]
Total events: 14 (Injection therapy), 12 (Control)
Heterogeneity: Chi2 = 7.99, df = 5 (P = 0.16); I2 =37%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Chi2 = 0.56, df = 1 (P = 0.45), I2 =0.0%
0.01 0.1 1 10 100
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(1) Injection therapy and exercise versus exercise; the event was a calf tear in the exercise group
(2) All events represent mild pain
(3) All events represent slight burning
(4) All events represent a mild skin reaction
(5) One tendon rupture
(6) Bruising at injection sites
Analysis 1.6. Comparison 1 Injection therapies versus placebo injection or no injection control, Outcome 6
Pain (VAS; score 0 to 100; 0 = no pain) up to 3 months.
Review: Injection therapies for Achilles tendinopathy
Comparison: 1 Injection therapies versus placebo injection or no injection control
Outcome: 6 Pain (VAS; score 0 to 100; 0 = no pain) up to 3 months
Study or subgroup Injection therapy Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Injury-causing agents
Alfredson 2005 10 41 (32) 10 65 (20) 12.1 % -24.00 [ -47.39, -0.61 ]
Yelland 2011 (1) 14 43 (20) 13 48 (20) 14.8 % -5.00 [ -20.10, 10.10 ]
Subtotal (95% CI) 24 23 26.8 % -12.31 [ -30.43, 5.81 ]
Heterogeneity: Tau2 = 79.63; Chi2 = 1.79, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 1.33 (P = 0.18)
2 Direct repair agents
Chouchane 1989 14 16 (20) 18 78 (24) 14.7 % -62.00 [ -77.25, -46.75 ]
Fabbro 2012 (2) 18 7 (20) 18 31 (24) 15.0 % -24.00 [ -38.43, -9.57 ]
Fredberg 2004 (3) 12 17 (20) 12 28 (24) 13.9 % -11.00 [ -28.68, 6.68 ]
Larsen 1987 (4) 10 6 (20) 10 10 (24) 13.4 % -4.00 [ -23.36, 15.36 ]
Pforringer 1994 (5) 30 24 (20) 30 52 (20) 16.2 % -28.00 [ -38.12, -17.88 ]
Subtotal (95% CI) 84 88 73.2 % -26.34 [ -44.13, -8.55 ]
Heterogeneity: Tau2 = 349.42; Chi2 = 28.82, df = 4 (P<0.00001); I2 =86%
Test for overall effect: Z = 2.90 (P = 0.0037)
Total (95% CI) 108 111 100.0 % -22.94 [ -37.53, -8.36 ]
Heterogeneity: Tau2 = 316.00; Chi2 = 36.63, df = 6 (P<0.00001); I2 =84%
Test for overall effect: Z = 3.08 (P = 0.0021)
Test for subgroup differences: Chi2 = 1.17, df = 1 (P = 0.28), I2 =15%
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(1) Injection and exercise versus exercise; SD imputed from data of similar studies using the same outcome measure at same outcome point
(2) Injection therapy and dry needling versus dry needling; SD imputed from data of similar studies using the same outcome measure at same outcome point
(3) SD imputed from data of similar studies using the same outcome measure at same outcome point
(4) SD imputed from data of similar studies using the same outcome measure at same outcome point
(5) SD imputed from data of similar studies using the same outcome measure at same outcome point
Analysis 1.7. Comparison 1 Injection therapies versus placebo injection or no injection control, Outcome 7
Return to sports.
Review: Injection therapies for Achilles tendinopathy
Comparison: 1 Injection therapies versus placebo injection or no injection control
Outcome: 7 Return to sports
Study or subgroup Injection therapy Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Injury-causing agents
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Injection therapy), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Direct repair agents
Bell 2013 13/18 9/25 13.1 % 2.01 [ 1.11, 3.64 ]
Brown 2006 10/13 11/13 17.5 % 0.91 [ 0.62, 1.33 ]
Capasso 1993 50/77 6/20 11.5 % 2.16 [ 1.09, 4.31 ]
DaCruz 1988 10/19 9/16 12.9 % 0.94 [ 0.51, 1.72 ]
De Vos 2010 18/27 16/27 16.8 % 1.13 [ 0.75, 1.70 ]
Larsen 1987 7/10 6/10 12.2 % 1.17 [ 0.61, 2.23 ]
Pforringer 1994 28/30 12/30 16.0 % 2.33 [ 1.49, 3.65 ]
Subtotal (95% CI) 194 141 100.0 % 1.39 [ 1.00, 1.94 ]
Total events: 136 (Injection therapy), 69 (Control)
Heterogeneity: Tau2 = 0.13; Chi2 = 17.30, df = 6 (P = 0.01); I2 =65%
Test for overall effect: Z = 1.94 (P = 0.053)
Total (95% CI) 194 141 100.0 % 1.39 [ 1.00, 1.94 ]
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(. . . Continued)
Study or subgroup Injection therapy Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 136 (Injection therapy), 69 (Control)
Heterogeneity: Tau2 = 0.13; Chi2 = 17.30, df = 6 (P = 0.01); I2 =65%
Test for overall effect: Z = 1.94 (P = 0.053)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Injection therapies versus placebo injection or no injection control, Outcome 8
Patient satisfaction with treatment (an event represents satisfaction with treatment).
Review: Injection therapies for Achilles tendinopathy
Comparison: 1 Injection therapies versus placebo injection or no injection control
Outcome: 8 Patient satisfaction with treatment (an event represents satisfaction with treatment)
Study or subgroup Injection therapy Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Injury-causing agents
Alfredson 2005 5/10 0/10 1.4 % 11.00 [ 0.69, 175.86 ]
Yelland 2011 (1) 10/14 7/13 19.9 % 1.33 [ 0.73, 2.42 ]
Subtotal (95% CI) 24 23 21.4 % 2.79 [ 0.26, 29.91 ]
Total events: 15 (Injection therapy), 7 (Control)
Heterogeneity: Tau2 = 2.16; Chi2 = 3.07, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 0.85 (P = 0.40)
2 Direct repair agents
Bell 2013 23/25 24/26 50.3 % 1.00 [ 0.85, 1.17 ]
De Vos 2010 15/27 17/27 28.3 % 0.88 [ 0.57, 1.38 ]
Subtotal (95% CI) 52 53 78.6 % 0.98 [ 0.85, 1.14 ]
Total events: 38 (Injection therapy), 41 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.47, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
Total (95% CI) 76 76 100.0 % 1.05 [ 0.76, 1.47 ]
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(. . . Continued)
Study or subgroup Injection therapy Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 53 (Injection therapy), 48 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 5.71, df = 3 (P = 0.13); I2 =47%
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Chi2 = 0.74, df = 1 (P = 0.39), I2 =0.0%
0.005 0.1 1 10 200
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(1) Injection therapy and exercise versus exercise
Analysis 2.1. Comparison 2 Injection therapies versus active treatment, Outcome 1 VISA-A (score 0 to 100;
100 = no problems).
Review: Injection therapies for Achilles tendinopathy
Comparison: 2 Injection therapies versus active treatment
Outcome: 1 VISA-A (score 0 to 100; 100 = no problems)
Study or subgroup Injection therapy Active treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Direct repair agent vs exercises: at 6 weeks
Kearney 2013 10 56 (30) 10 49 (26) 7.00 [ -17.61, 31.61 ]
2 Direct repair agent vs exercises: at 3 months
Kearney 2013 10 63 (29) 9 56 (27) 7.00 [ -18.18, 32.18 ]
3 Direct repair agent vs exercises: after 3 months (6 months)
Kearney 2013 9 76 (23) 9 57 (27) 19.00 [ -4.17, 42.17 ]
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Analysis 2.2. Comparison 2 Injection therapies versus active treatment, Outcome 2 Patients achieving
increased VISA-A scores (20 points or more from baseline).
Review: Injection therapies for Achilles tendinopathy
Comparison: 2 Injection therapies versus active treatment
Outcome: 2 Patients achieving increased VISA-A scores (20 points or more from baseline)
Study or subgroup Injection therapy Active treatment Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Injury-causing agent vs exercises: 6 weeks
Yelland 2011 5/14 3/15 1.79 [ 0.52, 6.12 ]
2 Injury-causing agent vs exercises: 3 months
Yelland 2011 7/14 8/15 0.94 [ 0.46, 1.90 ]
3 Injury-causing agent vs exercises: 12 months
Yelland 2011 11/14 11/15 1.07 [ 0.71, 1.61 ]
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Analysis 2.3. Comparison 2 Injection therapies versus active treatment, Outcome 3 Adverse events.
Review: Injection therapies for Achilles tendinopathy
Comparison: 2 Injection therapies versus active treatment
Outcome: 3 Adverse events
Study or subgroup Injection therapy Active treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Injury-causing agent vs surgery
Alfredson 2007 (1) 0/10 1/10 50.0 % 0.33 [ 0.02, 7.32 ]
Subtotal (95% CI) 10 10 50.0 % 0.33 [ 0.02, 7.32 ]
Total events: 0 (Injection therapy), 1 (Active treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.49)
2 Injury-causing agent vs eccentric exercises
Yelland 2011 (2) 0/13 1/13 50.0 % 0.33 [ 0.01, 7.50 ]
Subtotal (95% CI) 13 13 50.0 % 0.33 [ 0.01, 7.50 ]
Total events: 0 (Injection therapy), 1 (Active treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
3 Direct repair agent vs eccentric exercises
Kearney 2013 0/10 0/10 Not estimable
Subtotal (95% CI) 10 10 Not estimable
Total events: 0 (Injection therapy), 0 (Active treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 33 33 100.0 % 0.33 [ 0.04, 2.99 ]
Total events: 0 (Injection therapy), 2 (Active treatment)
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 1.00), I2 =0.0%
0.01 0.1 1 10 100
Favours injection therapy Favours active treatment
(1) Adverse event: 1 deep wound infection
(2) Adverse event: 1 partial calf tear (playing tennis)
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Analysis 2.4. Comparison 2 Injection therapies versus active treatment, Outcome 4 Quality of life: EQ-5D
(scores up to 1: full health).
Review: Injection therapies for Achilles tendinopathy
Comparison: 2 Injection therapies versus active treatment
Outcome: 4 Quality of life: EQ-5D (scores up to 1: full health)
Study or subgroup Injection therapy Active treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Direct repair agent vs eccentric exercises
Kearney 2013 9 0.82 (0.35) 10 0.74 (0.39) 100.0 % 0.08 [ -0.25, 0.41 ]
Total (95% CI) 9 10 100.0 % 0.08 [ -0.25, 0.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours active treatment Favours injection therapy
Analysis 2.5. Comparison 2 Injection therapies versus active treatment, Outcome 5 Patient satisfaction
with treatment (satisfied patients).
Review: Injection therapies for Achilles tendinopathy
Comparison: 2 Injection therapies versus active treatment
Outcome: 5 Patient satisfaction with treatment (satisfied patients)
Study or subgroup Injection therapy Active treatment Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Injury-causing agent vs surgery
Alfredson 2007 6/10 10/10 0.62 [ 0.37, 1.03 ]
2 Injury-causing agent vs eccentric exercises
Yelland 2011 9/13 7/13 1.29 [ 0.69, 2.39 ]
0.2 0.5 1 2 5
Favours active treatment Favours injection therapy
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Analysis 3.1. Comparison 3 High-dose versus low-dose injection therapy, Outcome 1 Adverse events.
Review: Injection therapies for Achilles tendinopathy
Comparison: 3 High-dose versus low-dose injection therapy
Outcome: 1 Adverse events
Study or subgroup High dose injection Low dose injection Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Willberg 2008 (1) 0/26 0/26 Not estimable
0.5 0.7 1 1.5 2
Favours high dose Favours low dose
(1) Comparison: 10 mg/ml vs. 5 mg/ml Polidocanol injection
Analysis 3.2. Comparison 3 High-dose versus low-dose injection therapy, Outcome 2 Pain during activity
(VAS; score 0 to 100; 0 = no pain) after maximum of 3 treatments.
Review: Injection therapies for Achilles tendinopathy
Comparison: 3 High-dose versus low-dose injection therapy
Outcome: 2 Pain during activity (VAS; score 0 to 100; 0 = no pain) after maximum of 3 treatments
Study or subgroup High dose injection Low dose injection
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Willberg 2008 (1) 26 24 (31) 26 25 (28) -1.00 [ -17.06, 15.06 ]
-100 -50 0 50 100
Favours high dose Favours low dose
(1) Comparison: 10 mg/ml vs. 5 mg/ml Polidocanol injection
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Analysis 3.3. Comparison 3 High-dose versus low-dose injection therapy, Outcome 3 Patient satisfaction
(satisfied patients).
Review: Injection therapies for Achilles tendinopathy
Comparison: 3 High-dose versus low-dose injection therapy
Outcome: 3 Patient satisfaction (satisfied patients)
Study or subgroup High dose injection Low dose injection Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 After 3 treatments
Willberg 2008 (1) 19/26 20/26 0.95 [ 0.69, 1.30 ]
2 After 5 treatments
Willberg 2008 (2) 26/26 26/26 1.00 [ 0.93, 1.08 ]
0.2 0.5 1 2 5
Favours low dose Favours high dose
(1) Comparison: 10 mg/ml vs. 5 mg/ml Polidocanol injection
(2) Comparison: 10 mg/ml vs. 5 mg/ml Polidocanol injection
A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL (Wiley Online Library)
2014, Issue 1
#1 MeSH descriptor: [Achilles Tendon] this term only (201)
#2 Achilles or calcan*:ti,ab,kw (Word variations have been searched) (730)
#3 #1 or #2 (730)
#4 [mh Tendinopathy] or [mh ˆ“Athletic Injuries”] or [mh ˆ“Tendon Injuries”] or [mh ˆ“Soft Tissue Injuries”] (945)
#5 tend?nitis or tenosynovitis or tendinopath* or tendinosis or paratend?nitis or peritend?nitis:ti,ab,kw (Word variations have been
searched) (603)
#6 #4 or #5 (1249)
#7 #3 and #6 (171)
#8 [mh Înjections] or [mh ˆ“Injections, Intralesional”] (2476)
#9 injection*:ti,ab,kw (Word variations have been searched) (40536)
#10MeSHdescriptor: [AdrenalCortexHormones] explode all trees andwith qualifier(s): [Administration&dosage -AD, Pharmacology
- PD, Therapeutic use - TU] (5341)
#11MeSHdescriptor: [Steroids] explode all trees andwith qualifier(s): [Administration&dosage -AD, Pharmacology - PD,Therapeutic
use - TU] (25397)
#12 MeSH descriptor: [Anti-Inflammatory Agents] this term only (4585)
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#13 glucocorticoid* or corticoster* or methylprednisolone or prednisolone or betamethasone or triamcinolone or cortisone or hydro-
cortisone:ti,ab,kw (Word variations have been searched) (22661)
#14 “high volume”:ti,ab,kw (Word variations have been searched) (499)
#15 prolotherapy or “proliferation therapy”:ti,ab,kw (Word variations have been searched) (30)
#16 autologous near/3 blood:ti,ab,kw (Word variations have been searched) (1230)
#17 MeSH descriptor: [Blood Transfusion, Autologous] this term only (602)
#18 ((platelet rich near/3 (plasma or therap*)) or PRP):ti,ab,kw (Word variations have been searched) (889)
#19 MeSH descriptor: [Platelet-Rich Plasma] this term only (142)
#20 MeSH descriptor: [Aprotinin] this term only (528)
#21 Aprotinin:ti,ab,kw (Word variations have been searched) (816)
#22 MeSH descriptor: [Botulinum Toxins] explode all trees (829)
#23 “botulinum toxin”:ti,ab,kw (Word variations have been searched) (1374)
#24 “sodium hyaluronate”:ti,ab,kw (Word variations have been searched) (393)
#25 MeSH descriptor: [Glycosaminoglycans] this term only (215)
#26 Glycosaminoglycan*:ti,ab,kw (Word variations have been searched) (367)
#27 [mh ˆ“Sclerosing Solutions”] or [mh ˆSclerotherapy] (638)
#28 MeSH descriptor: [Polyethylene Glycols] this term only (1675)
#29 polidocanol:ti,ab,kw (Word variations have been searched) (164)
#30 lauromacrogol:ti,ab,kw (Word variations have been searched) (2)
#31 “hyperosmolar dextrose”:ti,ab,kw (Word variations have been searched) (3)
#32 {or #8-#31} (82892)
#33 #7 and #32 (33) [Trials]
The top-up search in April 2015 found 46 records (no date restrictions were applied to this search)
MEDLINE (Ovid Online)
1946 to February 2014
1 Achilles Tendon/ (5825)
2 (Achilles or calcan*).tw. (14547)
3 1 or 2 (15986)
4 exp Tendinopathy/ or Athletic Injuries/ or Tendon Injuries/ or Soft Tissue Injuries/ (38022)
5 (Tend#nitis or tenosynovitis or tendinopath* or tendinosis or paratend#nitis or peritend#nitis).tw. (6355)
6 4 or 5 (40263)
7 3 and 6 (3052)
8 Injections/ or Injections, Intralesional/ (37991)
9 injection*.tw. (436022)
10 exp Adrenal Cortex Hormones/ad, dt, pd, tu [Administration &Dosage, Drug Therapy, Pharmacology, Therapeutic Use] (198119)
11 exp Steroids/ (690880)
12 Anti-Inflammatory Agents/ (54257)
13 (glucocorticoid* or corticoster* or methylprednisolone or prednisolone or betamethasone or triamcinolone or cortisone or hydro-
cortisone).tw. (185628)
14 “high volume”.tw. (7066)
15 (prolotherapy or “proliferation therapy”).tw. (105)
16 (autologous adj3 blood).tw. (8067)
17 Blood Transfusion, Autologous/ (6584)
18 ((platelet rich adj3 (plasma or therap*)) or PRP).tw. (13910)
19 Platelet-Rich Plasma/ (1410)
20 Aprotinin/ (6164)
21 Aprotinin.tw. (4080)
22 exp Botulinum Toxins/ (12118)
23 “botulinum toxin”.tw. (8901)
24 “sodium hyaluronate”.tw. (1328)
25 Glycosaminoglycans/ (21879)
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26 glycosaminoglycan.tw. (10105)
27 Sclerosing Solutions/ or Sclerotherapy/ (7508)
28 Polyethylene Glycols/ (36754)
29 polidocanol.tw. (520)
30 lauromacrogol.tw. (6)
31 “hyperosmolar dextrose”.tw. (16)
32 or/8-31 (1347665)
33 7 and 32 (346)
34 Randomized controlled trial.pt. (363145)
35 Controlled clinical trial.pt. (87554)
36 randomized.ab. (283334)
37 placebo.ab. (149893)
38 Drug therapy.fs. (1663527)
39 randomly.ab. (205978)
40 trial.ab. (292168)
41 groups.ab. (1317336)
42 or/34-41 (3254461)
43 exp Animals/ not Humans/ (3880949)
44 42 not 43 (2788526)
45 33 and 44 (134)
The top-up search in April 2015 found 14 records.
EMBASE (Ovid Online)
1974 to February 2014
1 Achilles Tendinitis/ (688)
2 Achilles Tendon/ (6523)
3 (Achill* or calcan*).tw. (19770)
4 2 or 3 (21334)
5 Tendinitis/ or Tenosynovitis/ or Sport Injury/ or Tendon Injury/ or Soft Tissue Injury/ (46247)
6 (tend#nitis or tenosynovitis or tendinopath* or tendinosis or paratend#nitis or peritend#nitis).tw. (8323)
7 5 or 6 (48590)
8 4 and 7 (3272)
9 1 or 8 (3549)
10 Injection/ or Intralesional Drug Administration/ (70292)
11 injection*.tw. (551885)
12 exp Corticosteroid/ (729149)
13 exp Antiinflammatory Agent/ (1232211)
14 (glucocorticoid* or corticoster* or methylprednisolone or prednisolone or betamethasone or triamcinolone or cortisone or hydro-
cortisone).tw. (244765)
15 “high volume”.tw. (10915)
16 (prolotherapy or “proliferation therapy”).tw. (164)
17 (autologous adj3 blood).tw. (10388)
18 exp Blood Transfusion/ (130039)
19 ((platelet rich adj3 (plasma or therap*)) or PRP).tw. (17170)
20 Plasma Transfusion/ or Thrombocyte Rich Plasma/ (7628)
21 Aprotinin/ (12571)
22 aprotinin.tw. (5030)
23 Botulinum Toxin/ (11498)
24 “botulinum toxin”.tw. (12192)
25 “sodium hyaluronate”.tw. (1897)
26 Glycosaminoglycan/ (26125)
27 glycosaminoglycan.tw. (11628)
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28 Sclerosing Agent/ or Sclerotherapy/ (11224)
29 Macrogol derivative/ (12133)
30 Polidocanol/ (3278)
31 polidocanol.tw. (803)
32 lauromacrogol.tw. (22)
33 “hyperosmolar dextrose”.tw. (20)
34 or/10-33 (2156429)
35 and/9,34 (770)
36 exp Randomized Controlled Trial/ or exp Single Blind Procedure/ or expDouble Blind Procedure/ or Crossover Procedure/ (417550)
37 (random* or RCT or placebo or allocat* or crossover* or ’cross over’ or trial or (doubl* adj1 blind*) or (singl* adj1 blind*)).ti,ab.
(1288581)
38 36 or 37 (1369001)
39 (exp Animal/ or animal.hw. or Nonhuman/) not (exp Human/ or Human cell/ or (human or humans).ti.) (5569950)
40 38 not 39 (1204310)
41 35 and 40 (93)
The top-up search in April 2015 found 12 records
AMED (Ovid Online)
1985 to February 2014
1 Achilles Tendon/ (592)
2 (Achilles or calcan*).tw. (2085)
3 1 or 2 (2085)
4 Tendinopathy/ or Tenosynovitis/ or exp Athletic Injuries/ or Tendon Injuries/ (4234)
5 (tend#nitis or tenosynovitis or tendinopath* or tendinosis or paratend#nitis or peritend#nitis).tw. (705)
6 4 or 5 (4548)
7 3 and 6 (517)
8 Randomized controlled trial.pt. (2853)
9 Controlled clinical trial.pt. (70)
10 Randomized Controlled Trials/ (1649)
11 Random Allocation/ (311)
12 Double-Blind Method/ (500)
13 or/8-12 (5129)
14 exp Animals/ not Humans/ (7399)
15 13 not 14 (5100)
16 clinical trial.pt. (1158)
17 exp Clinical trials/ (3352)
18 (clinic$ adj25 trial$).tw. (5818)
19 ((singl$ or doubl$ or trebl$ or tripl$) adj (mask$ or blind$)).tw. (2324)
20 Placebos/ (545)
21 placebo$.tw. (2635)
22 random$.tw. (14004)
23 exp Research design/ (17849)
24 (latin adj square).tw. (24)
25 or/16-24 (31349)
26 25 not 14 (30812)
27 26 not 15 (25847)
28 7 and 27 (62)
The top-up search in April 2015 found 2 records
CINAHL (EBSCO)
1981 to February 2014
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S1 (MH “Achilles Tendinopathy”) (406)
S2 (MH “Achilles Tendon”) (1,557)
S3 TI ( Achill* or calcan* ) OR AB ( Achill* or calcan* ) (3,618)
S4 S2 OR S3 (3,968)
S5 (MH “Tendinopathy”) OR (MH “Tenosynovitis”) OR (MH “Athletic Injuries”) OR (MH “Tendon Injuries”) OR (MH “Soft
Tissue Injuries”) (16,600)
S6 TX tendinitis ot tendonitis or tenosynovitis or tendinopath* or tendinosis or paratendinitis or paratendonitis or peritendinitis or
peritendonitis (2,761)
S7 S5 OR S6 (17,415)
S8 S4 AND S7 (1,103)
S9 S1 AND S8 (304)
S10 (MH “Injections”) OR (MH “Injections, Intralesional”) (7,118)
S11 TI injection* OR AB injection* (21,165)
S12 (MH “Adrenal Cortex Hormones+”) (19,001)
S13 (MH “Antiinflammatory Agents”) (5,385)
S14 TX (glucocorticoid* or corticoster* or methylprednisolone or prednisolone or betamethasone or triamcinolone or cortisone or
hydrocortisone) (21,247)
S15 TX “high volume” (1,170)
S16 TX (prolotherapy or “proliferation therapy”) (141)
S17 TX (autologous n3 blood) (1,185)
S18 (MH “Blood Transfusion, Autologous”) (814)
S19 ((platelet rich n3 (plasma or therap*)) or PRP) (962)
S20 (MH “Platelet-Rich Plasma”) (107)
S21 (MH “Aprotinin”) (354)
S22 TX aprotinin (435)
S23 (MH “Botulinum Toxins”) (3,163)
S24 TX “botulinum toxin” (2,060)
S25 TX “sodium hyaluronate” (105)
S26 (MH “Glycosaminoglycans”) (505)
S27 TX glycosaminoglycan* (700)
S28 (MH “Sclerosing Solutions”) OR (MH “Sclerotherapy”) (759)
S29 (MH “Polyethylene Glycols”) (754)
S30 TX polidocanol (39)
S31 TX lauromacrogol (0)
S32 TX “hyperosmolar dextrose” (6)
S33 S3 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23
OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 (65,862)
S34 S9 AND S33 (297)
S35 (MH “Clinical Trials+”) (171,321)
S36 (MH “Evaluation Research+”) (20,176)
S37 (MH “Comparative Studies”) (75,438)
S38 (MH “Crossover Design”) (11,400)
S39 PT Clinical Trial (75,447)
S40 (MH “Random Assignment”) (36,644)
S41 S35 or S36 or S37 or S38 or S39 or S40 (271,532)
S42 TX ((clinical or controlled or comparative or placebo or prospective or randomi?ed) and (trial or study)) (476,924)
S43 TX (random* and (allocat* or allot* or assign* or basis* or divid* or order*)) (65,094)
S44 TX ((singl* or doubl* or trebl* or tripl*) and (blind* or mask*)) (716,865)
S45 TX ( crossover* or ’cross over’ ) or TX cross n1 over (14,250)
S46 TX ((allocat* or allot* or assign* or divid*) and (condition* or experiment* or intervention* or treatment* or therap* or control*
or group*)) (81,724)
S47 S42 or S43 or S44 or S45 or S46 (1,103,137)
S48 S41 or S47 (1,168,734)
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S49 S34 AND S48 (148)
The top-up search in April 2015 found 21 records
SPORTDiscus (EBSCO)
1985 to February 2014
S1 DE “ACHILLES tendinitis” (220)
S2 (DE “ACHILLES tendon”) OR (DE “ACHILLES tendon -- Wounds & injuries”) (2,098)
S3 TX Achill* or calcan* (4,537)
S4 S2 OR S3 (4,537)
S5 (DE “TENDINITIS”) OR (DE “TENOSYNOVITIS”) OR (DE “SOFT tissue injuries”) OR (DE “SPORTS injuries”) (8,224)
S6 TX tendinitis ot tendonitis or tenosynovitis or tendinopath* or tendinosis or paratendinitis or paratendonitis or peritendinitis or
peritendonitis (1,729)
S7 S5 OR S6 (9,108)
S8 S4 AND S7 (972)
S9 S1 OR S8 (1,015)
S10 DE “INJECTIONS” (875)
S11 TX injection* (6,591)
S12 DE “ANTI-inflammatory agents” (752)
S13 TX (glucocorticoid* or corticoster* or methylprednisolone or prednisolone or betamethasone or triamcinolone or cortisone or
hydrocortisone) (4,038)
S14 TX “high volume” (425)
S15 TX (prolotherapy or “proliferation therapy”) (55)
S16 TX (autologous n3 blood) (94)
S17 TX ((platelet rich n3 (plasma or therap*)) or PRP) (320)
S18 TX aprotinin (44)
S19 DE “BOTULINUM toxin” (486)
S20 TX “botulinum toxin” (581)
S21 TX “sodium hyaluronate” (24)
S22 TX glycosaminoglycan* (173)
S23 TX sclerosing solution* or sclerotherap* (54)
S24 TX polyethylene glycol* (89)
S25 TX polidocanol (48)
S26 TX lauromacrogol (0)
S27 TX hyperosmolar dextrose (5)
S28 S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24
OR S25 OR S26 OR S27 (11,840)
S29 S9 AND S28 (149)
S30 TX ( (clinic* N3 trial) or (controlled N3 trial) or (comparative N3 trial) or (placebo N3 trial) or (prospective N3 trial) or (randomi?
ed N3 trial) ) or TX ( (clinic* N3 study) or (controlled N3 study) or (comparative N3 study) or (placebo N3 study) or (prospective
N3 study) or (randomi?ed N3 study) ) (63,486)
S31 (random* N7 allot*) or (random* N7 assign*) or (random* N7 basis*) or (random* N7 divid*) or (random* N7 order*) (8,164)
S32 TX ( (singl* N7 blind*) or (doubl* N7 blind*) or (trebl* N7 blind*) or (tripl* N7 blind*) ) or TX ( (singl* N7 mask*) or (doubl*
N7 mask*) or (trebl* N7 mask*) or (tripl* N7 mask*) ) (5,124)
S33 TX (cross#over*) or TX (cross N1 over*) (3,545)
S34 TX randomi?ed control* trial* (7,589)
S35 TX ( (allocat* N3 condition*) or (allocat* N3 experiment*) or (allocat* N3 intervention*) or (allocat* N3 treatment*) or (allocat*
N3 therap*) or (allocat* N3 control*) or (allocat* N3 group*) ) or TX ( (allot* N3 condition*) or (allot* N3 experiment*) or (allot*
N3 intervention*) or (allot* N3 treatment*) or (allot* N3 therap*) or (allot* N3 control*) or (allot* N3 group*) ) or TX ( (assign* N3
condition*) or (assign* N3 experiment*) or (assign* N3 intervention*) or (assign* N3 treatment*) or (assign* N3 therap*) or (assign*
N3 control*) or (assign* N3 group*) ) or TX ( (divid* N3 condition*) or (divid* N3 experiment*) or (divid* N3 intervention*) or
(divid* N3 treatment*) or (divid* N3 therap*) or (divid* N3 control*) or (divid* N3 group*) )( 8,484)
S36 TX placebo* (7,506)
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S37 S30 or S31 or S32 or S33 or S34 or S35 or S36 (77,885)
S38 S29 AND S37 (56)
The top-up search in April 2015 found 2 records
ISRCTN registry
May 2014
1. Achilles (19)
WHO ICTRP
May 2014
1. Achilles (95)
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External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The current protocol differs from the originally published protocol in three ways:
1. Inclusion of a surgical management comparison arm.
2. Combining serious and non-serious adverse events into the same analysis.
3. Imputation of standard deviations in cases where standard deviations for the same outcome measure at the same outcome time
point were available from other studies in the review.
N O T E S
Future updates
A future update on this topic will consider the following:
• Inclusion of recurrence of tendinopathy where longer-term follow-up is available.
• Subgroup analysis per injection type.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Achilles Tendon; Adrenal Cortex Hormones [administration & dosage]; Aprotinin [administration & dosage]; Athletes; Fibroblasts
[transplantation]; Glycosaminoglycans [administration & dosage]; Hemodialysis Solutions [administration & dosage]; Injections,
Intralesional [adverse effects; ∗methods]; PlateletTransfusion; PolyethyleneGlycols [administration &dosage]; Randomized Controlled
Trials as Topic; Sodium Chloride [administration & dosage]; Tendinopathy [∗therapy]
MeSH check words
Adult; Humans; Middle Aged; Young Adult
75Injection therapies for Achilles tendinopathy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
